

1 **High-contrast in-vivo imaging of**
2 **tau pathologies in Alzheimer's**
3 **and non-Alzheimer's disease tauopathies**
4

5 **AUTHORS/AFFILIATIONS:**

6 Kenji Tagai^{1,2,14}, Maiko Ono^{1,14}, Manabu Kubota^{1,3,14}, Soichiro Kitamura^{1,4}, Keisuke
7 Takahata^{1,5}, Chie Seki¹, Yuhei Takado¹, Hitoshi Shinotoh^{1,6}, Yasunori Sano^{1,5}, Kiwamu
8 Matsuoka^{1,4}, Hiroyuki Takuwa¹, Masafumi Shimojo¹, Manami Takahashi¹, Kazunori
9 Kawamura¹, Tatsuya Kikuchi¹, Maki Okada¹, Haruhiko Akiyama⁷, Hisaomi Suzuki^{1,5,8},
10 Mitsumoto Onaya⁸, Takahiro Takeda⁹, Kimihito Arai⁹, Nobutaka Arai¹⁰, Nobuyuki Araki⁹,
11 Yuko Saito¹¹, Yasuyuki Kimura^{1,12}, Masanori Ichise¹, Yutaka Tomita¹³, Ming-Rong
12 Zhang¹, Tetsuya Suhara^{1,2}, Masahiro Shigeta², Naruhiko Sahara¹, Makoto Higuchi^{1*},
13 Hitoshi Shimada¹

14
15 ¹National Institute of Radiological Sciences, National Institutes for Quantum and
16 Radiological Science and Technology, Chiba 263-8555, Japan

17 ²Department of Psychiatry, The Jikei University Graduate School of Medicine, Tokyo
18 105-8461, Japan

19 ³Department of Psychiatry, Kyoto University Graduate School of Medicine 54 Shogoin-
20 Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan

21 ⁴Department of Psychiatry, Nara Medical University, Nara 634-8521, Japan

22 ⁵Department of Psychiatry, Keio University School of Medicine, Tokyo 160-0016, Japan

23 ⁶Neurology Clinic Chiba, Chiba 263-8555, Japan

24 ⁷Dementia Research Project, Tokyo Metropolitan Institute of Medical Science, Tokyo
25 156-8506, Japan

26 ⁸National Hospital Organization Shimofusa Psychiatric Medical Center, Chiba 266-0007,
27 Japan

28 ⁹Department of Neurology, National Hospital Organization Chibahigashi National
29 Hospital, Chiba 260-8712, Japan

30 ¹⁰Laboratory of Neuropathology, Tokyo Metropolitan Institute of Medical Science, Tokyo
31 156-8506, Japan

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

1 ¹¹National Center of Neurology and Pathology Brain Bank, National Center Hospital,
2 National Center of Neurology and Psychiatry, Tokyo, Japan

3 ¹²Department of Clinical and Experimental Neuroimaging, Center for Development of
4 Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Aichi
5 474-8511, Japan

6 ¹³Tomita Hospital, Aichi 444-3505, Japan

7 ¹⁴These authors contributed equally to this work.

8 * Correspondence: higuchi.makoto@qst.go.jp (M.Higuchi)

9

10 **SUMMARY**

11 A panel of radiochemicals has enabled *in-vivo* positron emission tomography (PET) of
12 tau pathologies in Alzheimer's disease (AD), while sensitive detection of frontotemporal
13 lobar degeneration (FTLD) tau inclusions has been unsuccessful. Here, we generated an
14 imaging probe, PM-PBB3, for capturing diverse tau deposits. *In-vitro* assays
15 demonstrated the reactivity of this compound with tau pathologies in AD and FTLD. We
16 could also utilize PM-PBB3 for optical/PET imaging of a living murine tauopathy model.
17 A subsequent clinical PET study revealed increased binding of ¹⁸F-PM-PBB3 in diseased
18 patients, reflecting cortical-dominant AD and subcortical-dominant PSP tau topologies.
19 Notably, the *in-vivo* reactivity of ¹⁸F-PM-PBB3 with FTLD tau inclusion was strongly
20 supported by neuropathological examinations of autopsied and biopsied brains derived
21 from Pick's disease, PSP and corticobasal degeneration patients who underwent PET
22 scans. Finally, visual inspection of ¹⁸F-PM-PBB3-PET images was indicated to facilitate
23 individually based identification of diverse clinical phenotypes of FTLD on the
24 neuropathological basis.

25 (150 words)

26

27 **KEY WORDS:** tauopathies, *In-vivo* imaging, PET, mouse, Alzheimer's disease,
28 progressive supranuclear palsy, frontotemporal lobar degeneration.

29

30

31

1 INTRODUCTION

2 The vast majority of age-related neurodegenerative diseases are characterized as
3 protein conformational disorders, involving self-assemblies of misfolded proteins into
4 fibrillary aggregates (Soto and Pritzkow, 2018; Walker and Jucker, 2015). Among these
5 pathogenic proteins, the fibrillogenesis of microtubule-associated protein tau occurs as a
6 hallmark pathological change in diverse illnesses referred to as tauopathies, and it is
7 mechanistically linked to the neurodegenerative processes in these disorders (Iqbal et al.,
8 2016; Spillantini and Goedert, 2013). Tau in the central nervous system is composed of
9 six isoforms, which are classified into three- and four-repeat species according to the
10 number of repeat domains (Buee et al., 2000). Alzheimer's disease (AD) and AD-type
11 primary age-related tauopathy (PART) are characterized by tau pathologies formed by all
12 isoforms, while a significant subset of frontotemporal lobar degeneration (FTLD)
13 syndromes is neuropathologically unfolded by exclusive fibrillization of either three- or
14 four-repeat tau isoforms (Buee et al., 2000; Lee et al., 2001). The differences in the
15 isoform composition among these tauopathies lead to diversities in the conformation and
16 ultrastructures of tau fibrils as revealed by recent cryo-electron microscopic assays
17 (Falcon et al., 2018; Fitzpatrick et al., 2017).

18 The distinct tau conformers are likely to determine subcellular, cellular, and regional
19 localization of tau deposits in a disease-specific fashion, provoking characteristic
20 symptoms associated with deteriorations of affected neurons and neural circuits (Forrest
21 et al., 2019). In line with this mechanism, there exist clear distinctions among
22 neuropathological features of AD/PART and major tau-positive FTLD disorders,
23 including three-repeat tauopathies represented by Pick's disease (PiD) and four-repeat
24 tauopathies exemplified by progressive supranuclear palsy (PSP) and corticobasal
25 degeneration (CBD) (Lee et al., 2001). Meanwhile, substantial overlaps have been noted
26 among symptomatic phenotypes derived from these pathologies, impeding the
27 differentiation of clinical syndromes by estimation of underlying pathological alterations
28 (Rabinovici and Miller, 2010; Williams and Lees, 2009; Zhang et al., 2020).

29 *In-vivo* imaging technologies such as positron emission tomography (PET) with
30 specific radioligands for amyloid-beta and tau fibrils have enabled visualization of AD-
31 type neuropathologies in living subjects, facilitating diagnosis and staging of AD

1 dementia and its prodrome. The tau PET probes available for these clinical assays are
2 classified into three chemotypes consisting of ^{18}F -labeled THK5351 (Harada et al., 2016),
3 ^{18}F -labeled flortaucipir (Chien et al., 2014), and ^{11}C -labeled PBB3 (Maruyama et al.,
4 2013; Shimada et al., 2017) series originating from nonclinical prototypes BF-158/BF-
5 170 (Okamura et al., 2005), BF-126 (Okamura et al., 2005), and styryl 7 (PBB5)
6 (Maruyama et al., 2013), respectively. Unlike for AD tau lesions, high-contrast PET
7 detection of three- and four-repeat tau deposits in FTLD patients has been unsuccessful,
8 as tau-related radiosignals yielded by ^{18}F -flortaucipir and ^{11}C -PBB3 in PSP and CBD
9 cases were less than 20% of the corresponding signals in patients with advanced AD
10 (Endo et al., 2019; Schonhaut et al., 2017). ^{18}F -THK5351 was reported to illuminate brain
11 areas putatively enriched with PSP and CBD tau inclusions (Brendel et al., 2017; Kikuchi
12 et al., 2016), but those observations were attributed to the cross-reactivity of this
13 compound with monoamine oxidase B (MAO-B), which is upregulated in reactive
14 astrocytes (Harada et al., 2017; Ng et al., 2017). In addition, most ‘second-generation’ tau
15 PET probes are analogs of ^{18}F -flortaucipir and are not overtly more reactive with non-
16 AD tau assemblies than ^{18}F -flortaucipir and ^{11}C -PBB3 (Aguero et al., 2019; Honer et al.,
17 2018; Matthias Brendel, 2019).

18 ^{11}C -PBB3 was originally designed to capture tau fibrils in a wide range of tauopathies
19 (Maruyama et al., 2013) and was demonstrated to react with three- and four-repeat tau
20 aggregates in human brain tissues with a higher binding potential than ^{18}F -flortaucipir
21 (Ono et al., 2017). However, rapid conversion of ^{11}C -PBB3 into a metabolite resulted in
22 a relatively low entry of the unmetabolized compound into the brain (Hashimoto et al.,
23 2014; Kimura et al., 2015; Maruyama et al., 2013), hampering a sensitive recognition of
24 fibrillary aggregates in FTLD tauopathies that are less abundant than AD tau deposits. To
25 overcome this technical issue, in the current work we modified the chemical structure of
26 PBB3 to generate a chemical with a relatively high metabolic stability, aiming at
27 unambiguous investigations of tau fibril density and extent in each of the individuals with
28 AD and FTLD. The new compound, PM-PBB3 (propanol modification of PBB3), was
29 also fluorinated in consideration of advantages of an ^{18}F -labeled probe over ^{11}C -
30 radiochemicals for broader availability and higher PET scan throughput. Nonclinical
31 assays revealed the capability of PM-PBB3 for high-sensitivity illumination of tau

1 pathologies in a murine model bimodally by *in-vivo* optical and PET imaging from single-
2 cell to brain-wide scales, potentially serving for the discovery of candidate therapeutics
3 counteracting the neurodegenerative tau pathogenesis. Subsequent applications of ^{18}F -
4 PM-PBB3 to clinical PET assays, along with neuropathological data obtained from
5 scanned subjects, demonstrated appropriate kinetic and binding profiles of this probe for
6 personalized evaluations of tau depositions in AD and various FTLD syndromes.

7 8 9 **RESULTS**

10 ***In-vitro* binding of PM-PBB3 to AD- and FTLD-type tau aggregates**

11 The original compound, PBB3 (Figure 1a), was found to be promptly conjugated with
12 sulfate at a hydroxy moiety following systemic injection (Hashimoto et al., 2014). To
13 suppress this metabolic conversion, we substituted this substructure with the fluoro-
14 isopropanol group, resulting in the generation of PM-PBB3 (Figure 1a). This
15 modification also allowed ^{18}F radiolabeling of the probe using a tosylate precursor (Figure
16 S1). Similar to PBB3 (Maruyama et al., 2013; Ono et al., 2017), PM-PBB3 is self-
17 fluorescent, and its reactivity with pathological tau fibrils is assessable by fluorescence
18 labeling of brain sections derived from tauopathy patients. Triple staining of brain slices
19 with PM-PBB3, antibody against phosphorylated tau (AT8), and Gallyas-Braak silver
20 impregnation (GB) demonstrated binding of PM-PBB3 to neurofibrillary tangles (NFT),
21 neuropil threads, and dystrophic neurites encompassing neuritic plaques in AD
22 hippocampal formation, which were composed of six tau isoforms (Figure 1b).
23 Furthermore, PM-PBB3 conspicuously illuminated Pick bodies constituted of three-
24 repeat tau isoforms in PiD frontal cortex and four-repeat tau lesions such as tufted
25 astrocytes in PSP striatum, astrocytic plaques in CBD striatum, and coiled bodies and
26 argyrophilic grains and threads in these tissues (Figure 1b).

27 We then radiosynthesized ^{18}F -PM-PBB3 and examined its *in-vitro* binding
28 characteristics. Autoradiography of tissue sections demonstrated that ^{18}F -PM-PBB3
29 radiosignals were intensely distributed in the anatomical structures enriched with AD and
30 PSP tau fibrils, as exemplified by gray matter of the hippocampal formation and inferior
31 temporal cortex in the AD brain and gray and white matter of the motor cortex in the PSP

1 brain (Figure 1c). Radioligand binding was profoundly abolished by excessive non-
2 radioactive PBB5 (Figure 1c). Localization of the autoradiographic labeling was in line
3 with histological features obtained from the same sections, as abundant NFTs and
4 neuropil threads in the AD subiculum (area 1), and coiled bodies and tufted astrocytes in
5 middle gray matter layers of the PSP motor cortex (area 3) were captured by non-
6 radiolabeled PM-PBB3 (areas 1, 3 in Figure 1d). In contrast, the lack of overt
7 autoradiographic radioligand binding spatially agreed with minimal PM-PBB3
8 fluorescence in white matter of the AD temporal cortex, and in superficial gray matter
9 layers of the PSP motor cortex (areas 2, 4 in Figure 1d).

10 We also quantified the affinity of ^{18}F -PM-PBB3 for tau aggregates in homogenized AD
11 frontal cortical and PSP motor cortical tissues. Radioligand binding in these tissues was
12 homologously blocked by non-radiolabeled PM-PBB3 in a concentration-dependent
13 fashion (Figure 1e), indicating binding saturability. ^{18}F -PM-PBB3 displayed high-affinity,
14 high-capacity binding in AD homogenates [dissociation constant (K_D), 7.63 nM;
15 concentration of binding components (B_{\max}), 5743 pmol/g; binding potential ($\text{BP} = B_{\max}$
16 / K_D), 752.7] (Figure 1f). The radioligand bound in PSP tissues with lower capacity but
17 higher affinity than in AD tissues (K_D , 3.44 nM; B_{\max} , 688.2 pmol/g; BP, 199.9). The BP
18 for [^{18}F]PM-PBB3 in PSP homogenates was 1.6 times higher than the value for
19 [^{11}C]PBB3 in the same samples (Ono et al., 2017). The binding of ^{18}F -PM-PBB3 in AD
20 homogenates was partially and heterologously blocked by BTA-1, which is a Pittsburgh
21 Compound-B (PiB) analog and binds to A β aggregates with high affinity, with a large
22 inhibition constant (K_i) value (379.1 nM) (Figure 1g), suggesting that ^{18}F -PM-PBB3 is
23 incapable of sensitively capturing A β deposits in AD homogenates (Klunk et al., 2001;
24 Ni et al., 2018). Moreover, the heterologous blockade by BTA-1 is likely to stem primarily
25 from its low-affinity binding to AD tau fibrils. Notably, minimal displacement of ^{18}F -PM-
26 PBB3 binding was observed in the presence of the monoamine oxidase A (MAO-A)
27 inhibitor clorgiline, or the (MAO-B) inhibitor selegiline, in AD frontal cortex
28 homogenates (Figure 1g), suggesting that ^{18}F -PM-PBB3 barely cross-reacts with off-
29 target binding sites on monoamine oxidases, unlike the reported binding of ^{18}F -THK5351
30 and ^{18}F -flortaucipir to MAO-B (Harada et al., 2017; Lemoine et al., 2018; Ng et al., 2017)
31 and/or MAO-A (Vermeiren et al., 2017).

1

2 **Optical and PET detection of tau deposits in living tauopathy model mice**

3 For assessing *in-vivo* interactions of PM-PBB3 with intracellular tau deposits, we
4 utilized a murine transgenic (Tg) model of tauopathies dubbed rTg4510, which
5 overexpresses a human four-repeat tau isoform with the P301L mutation causative of
6 familial FTLN (Sahara et al., 2014; Santacruz et al., 2005). ^{18}F -PM-PBB3 bound to tau
7 fibrils in homogenized forebrain tissues obtained from Tg with high affinity (K_D , 4.7 nM),
8 while there was no homologously displaceable radioligand binding in non-transgenic
9 (nTg) forebrain homogenates (Figure 2a). *Ex-vivo* autoradiography of brain tissues
10 collected from mice at 30 min after intravenous ^{18}F -PM-PBB3 injection demonstrated
11 accumulations of the radioligand in the Tg forebrain harboring neuronal tau inclusions
12 (Figure 2b). Conversely, there was no noticeable increase of ^{18}F -PM-PBB3 retentions in
13 the nTg forebrain (Figure 2b). In addition, the radioligand accumulation was minimal in
14 the Tg and nTg cerebellum, which was devoid of tau pathologies (Figure 2b). Triple
15 staining of brain sections used for *ex-vivo* autoradiography with PM-PBB3 fluorescence,
16 GB, and AT8 illustrated strong binding of PM-PBB3 to intracellular tau aggregates in the
17 hippocampus and neocortex of a Tg mouse (Figure 2c).

18 To assess the time course of *in-vivo* labeling of intraneuronal tau aggregates with PM-
19 PBB3, we conducted intravital two-photon laser fluorescence microscopy with a cranial
20 window to the somatosensory cortex of the Tg and nTg mice. Comparison of PM-PBB3
21 and PBB3 signals in the same field of view indicated rapid entry of these probes into the
22 brain after intravenous probe administration, reaching tau aggregates within 5 min (Figure
23 2d). Quantification of the background-corrected fluorescence intensity revealed that PM-
24 PBB3 yielded 3-fold higher peak fluorescence signals in the same neurons burdened with
25 tau aggregate than PBB3 (Figure 2e). In contrast, no noticeable increases in fluorescence
26 signals were produced by intravenously injected PM-PBB3 in neurons of nTg mice
27 (Figure 2d).

28 The *in-vivo* performance of ^{18}F -PM-PBB3 and ^{11}C -PBB3 as a PET probe was then
29 examined by a head-to-head comparison in the same mice (Figure 2f-h). ^{18}F -PM-PBB3
30 rapidly entered the brain after intravenous administration, and the peak radioactivity
31 uptake was 1.4-fold higher than that of ^{11}C -PBB3 (Figure 2g). This was followed by a

1 prompt washout of radioactivity from the brains of nTg mice, whereas the clearance was
2 retarded in the Tg forebrain, reflecting radioligand binding to tau deposits. ^{18}F -PM-PBB3
3 generated a more than 2-fold higher contrast for tau lesions in the Tg hippocampus
4 relative to nTg controls than ^{11}C -PBB3 (Figure 2h).

5 The high brain uptake and tau contrast by ^{18}F -PM-PBB3 versus ^{11}C -PBB3 were
6 primarily attributable to its stability against bio-metabolism, since unmetabolized ^{18}F -
7 PM-PBB3 accounted for 79.9% and 97.5% of the total radioactivity in plasma and brain,
8 respectively, in contrast to unchanged ^{11}C -PBB3 accounting for 2.5% and 72.4% of the
9 total radioactivity in plasma and brain, respectively, at 5 min after intravenous injection
10 (Table S1). ^{18}F -PM-PBB3 has been confirmed to be decomposed to a hydrophilic
11 radiometabolite in human plasma at a slower rate than metabolizing ^{11}C -PBB3 (Figure
12 S2) (Maruyama et al., 2013).

13

14 **High-contrast PET imaging of AD and PSP tau pathologies in humans enabled by** 15 **^{18}F -PM-PBB3**

16 Encouraged by nonclinical results, ^{18}F -PM-PBB3 was applied to PET imaging in
17 human subjects. As depicted in Figure 3a, the retention of ^{18}F -PM-PBB3 clearly
18 visualized the neocortical and limbic dominance of six tau isoform accumulations in an
19 AD patient and subcortical dominance of four-repeat tau depositions in a PSP patient with
20 Richardson's syndrome (PSP-Richardson), a PSP subcategory with a typical clinical
21 phenotype (Hoglinger et al., 2017), in sharp contrast to the low radiosignals sustained in
22 the parenchyma of elderly healthy control (HC) brains. In fact, intensification of PET
23 signals in the parieto-temporal and posterior cingulate cortices of the AD brain and the
24 subthalamic nucleus, midbrain, and globus pallidus of the PSP brain was in agreement
25 with the known distribution of tau pathologies in these diseases (Figure 3a).

26 The uptake of ^{18}F -PM-PBB3 peaked rapidly after radioligand injection and
27 subsequently declined by more than 50% across all regions of the HC brain in the next
28 30 min, resulting in uniformly low radioligand retention (Figure 3b). The clearance of
29 ^{18}F -PM-PBB3 was profoundly slowed in tau-burdened areas of the AD and PSP brains,
30 conceivably reflecting the specific radioligand binding to tau aggregates (Figure 3b). The
31 cerebellum was included in brain areas with the lowest radioactivity retention (Figure 3b),

1 supporting the use of cerebellar gray matter as a reference tissue with a minimal tau fibril
2 load for quantification of the radioligand binding. The target-to-reference ratio of the
3 radioactivity (standardized uptake value ratio; SUVR) was progressively increased in
4 affected brain areas until ~60 min after radioligand injection, and then it almost plateaued
5 at ~90 min (Figure 3c).

6 To examine the superiority of ^{18}F -PM-PBB3 to ^{11}C -PBB3 as a high-sensitivity tau PET
7 probe, we carried out a head-to-head comparison of PET data with these radioligands in
8 the same individuals. The peak uptake of ^{18}F -PM-PBB3 in the brain (Figure 3b) was
9 approximately 2-fold higher than that of ^{11}C -PBB3 (Figure S3), and nonspecific
10 radioactivity retentions in the basal ganglia and venous sinuses at high levels and several
11 neocortical areas at low levels were provoked in a HC subject by ^{11}C -PBB3 but not ^{18}F -
12 PM-PBB3 (Figure 3a). Meanwhile, radioactivity accumulations in the choroid plexus,
13 which were documented in the use of other tau radioligands including ^{18}F -flortaucipir
14 (Ikonomic et al., 2016; Lee et al., 2018; Lowe et al., 2016), were augmented in ^{18}F -
15 PM-PBB3-PET images as compared to PET data with ^{11}C -PBB3 (Figure 3a). There was
16 a significant correlation between regional SUVRs for ^{18}F -PM-PBB3 and ^{11}C -PBB3 in the
17 cortical volumes of interest (VOIs) in the AD brain ($r = 0.679$, $p = 0.001$) and subcortical
18 VOIs in the PSP brain ($r = 0.805$, $p < 0.001$) (Figure 3d, e; see Figure S4 for details of
19 the VOI definition), and the linear regression slopes indicated that ^{18}F -PM-PBB3
20 produced more than 2-fold higher contrasts for AD and PSP tau deposits than ^{11}C -PBB3
21 (Figure 3d, e).

22 As there was no significant correlation between SUVRs for ^{18}F -PM-PBB3 and ^{11}C -PiB
23 in AD patients ($r = 0.295$, $p = 0.268$) (Figure 3f), it is unlikely that PET data with ^{18}F -
24 PM-PBB3 can be considerably affected by its cross-reactivity with A β deposits.

25

26 **The utility of ^{18}F -PM-PBB3 for PET assessments of the topology and stage of AD-** 27 **spectrum and PSP tau pathologies**

28 We performed tau and A β PET scans with ^{18}F -PM-PBB3 and ^{11}C -PiB, respectively, for
29 three mild cognitive impairment (MCI) and 14 AD patients (mean age \pm SD, 70.7 ± 11.9
30 years) as well as 23 HCs (mean age \pm SD, 65.2 ± 7.9 years) in order to investigate the
31 ability of ^{18}F -PM-PBB3 to capture the advancement of AD-spectrum tau pathologies in

1 each individual. To this aim, we defined composite VOIs according to Braak's NFT stages
2 (Figure S4) (Cho et al., 2016; Scholl et al., 2016). The tau pathologies indicated by
3 individual PET data were classified into stages zero (unaffected stage; 22 HCs), I/II
4 (transentorhinal stage; one HC), III/IV (limbic stage; one MCI and three AD patient), and
5 V/VI (neocortical stage; two MCI and 11 AD patients) by identifying Braak's stage
6 composite VOIs with a regional Z score > 2.5. All HCs were negative for ¹¹C-PiB-PET,
7 and all MCI and AD patients were positive for ¹¹C-PiB-PET, judging from visual
8 inspection of the acquired images. Representative ¹⁸F-PM-PBB3-PET images
9 demonstrated expansions of radiosignals from the medial temporal cortex to the other
10 neocortical and limbic areas, along with progression of the NFT stage (Figure 4a, b). ¹⁸F-
11 PM-PBB3 SUVRs in stage I/II VOI were elevated in a subset of HCs, being overlapped
12 with the values in MCI and AD patients, and this may imply accumulations of tau fibrils
13 in the medial temporal cortex at a preclinical stage of AD or PART (Figure 4c). By
14 contrast, SUVRs in stage III/IV and V/VI VOIs were much less variable among HCs, and
15 all 17 AD-spectrum (MCI + AD) cases exhibited increased SUVR beyond the HC range
16 in either of these VOIs (Figure 4c). Moreover, the radioligand accumulation in stage V/VI
17 VOI (Figure 4c) was significantly correlated with the severity of dementia as assessed by
18 Clinical Dementia Rating Sum of Boxes (CDRSoB) ($r = 0.671$, $p = 0.003$) (Figure 4d),
19 whereas other stage VOIs did not show significant correlations. These results indicate
20 that ¹⁸F-PM-PBB3 could detect tau depositions at preclinical and prodromal stages in the
21 AD spectrum and PART and that the formation of ¹⁸F-PM-PBB3-positive tau fibrils is
22 intimately associated with functional deteriorations of neocortical neurons in subjects
23 with cognitive declines.

24 The utility of ¹⁸F-PM-PBB3 for evaluations of four-repeat tau pathologies was also
25 examined in 16 PSP-Richardson patients who were negative for ¹¹C-PiB-PET (mean age
26 \pm SD, 71.5 ± 6.5 years). Severities of the disease in these cases were assessed using PSP
27 Rating Scale (PSPRS), which is a sensitive measure to evaluate global disability,
28 including the activity of daily living, motor, and mental disabilities, and to predict
29 prognosis in clinical practice (Golbe and Ohman-Strickland, 2007). High ¹⁸F-PM-PBB3
30 retention was observed in the subthalamic nucleus and midbrain of PSP patients relative
31 to HCs, was progressively intensified within these subcortical structures, and was

1 expanded to the neocortical area, including the gray and white matter of the primary motor
2 cortex together with increase in PSPRS scores (Figure 5a). Voxel-wise PET and magnetic
3 resonance imaging (MRI) assays revealed high spatial accordance of the radioligand
4 accumulation and brain atrophy in the subthalamic nucleus and midbrain as compared to
5 HCs (Figure 5b). VOI-based analyses also showed significant elevations of the
6 radioligand SUVRs in the subcortical areas of PSP patients compared to HCs (Figure 5c).
7 In particular, SUVR in the subthalamic nucleus, which is one of the regions most severely
8 affected by PSP tau pathologies (Williams et al., 2007), was increased in all PSP cases
9 with little overlap with HC values (Figure 5c), and was closely significantly correlated
10 with PSPRS scores (Figure 5d) ($r = 0.566, p = 0.018$).

12 **Intraindividual links between ^{18}F -PM-PBB3 PET data and tau pathologies in biopsy 13 and autopsy brain tissues proven in CBD, PSP and PiD patients**

14 We obtained histopathological evidence that *in-vivo* ^{18}F -PM-PBB3 binding reflects the
15 abundance of three- and four-repeat tau inclusions in patients with biopsy- and autopsy-
16 confirmed FTLD tauopathies. A clinical phenotype case of corticobasal syndrome (CBS)
17 underwent a brain biopsy to investigate the presence of a tumor in consideration of a low-
18 intensity lesion discovered by T1-weighted MRI as reported by Arakawa *et al.* (Arakawa
19 et al., 2020) (Figure S5). Neuropathological and biochemical examinations of the
20 biopsied sample from the middle frontal gyrus revealed the presence of anti-four-repeat
21 tau-specific antibody (RD4) and/or GB positive astrocytic plaques, ballooned neurons,
22 neuropil threads, and coiled bodies resulting from the formation of insoluble four-repeat
23 tau aggregates, which are characteristic of CBD (Arakawa et al., 2020) (Figure 6a).
24 Subsequent PET scans of this case showed negativity for ^{11}C -PiB and notable increases
25 of ^{18}F -PM-PBB3 retentions in the primary motor cortex, basal ganglia, and brainstem
26 consistent with the regional localization of CBD tau pathologies (Kouri et al., 2011), and
27 middle frontal gyrus (Figure 6a and S5)

28 Brain autopsy was also performed for a PSP-Richardson patient who had received an
29 ^{18}F -PM-PBB3 PET scan (see Supplemental Materials for clinical information), and a
30 definitive diagnosis of PSP (Cairns et al., 2007) was made on the basis of
31 neuropathological observations. *In-vivo* ^{18}F -PM-PBB3 radiosignals in the brain

1 parenchyma were primarily concentrated in the subthalamic nucleus and midbrain
2 (Figures 3a, 5a (asterisked images), 6b and 7 (top row)). Histochemical and
3 immunohistochemical analyses of the autopsied specimen identified a high abundance of
4 GB- and AT8-stained tufted astrocytes in the tegmentum and substantia nigra of the
5 midbrain and subthalamic nucleus, and these tau inclusions were fluorescently labeled
6 with nonradioactive PM-PBB3 (Figures 6b). In addition, GB-positive tufted astrocytes
7 were also distributed with high abundance in the globus pallidus and lower abundance in
8 the cerebral crus, internal capsule, and thalamus, which could contribute to the subcortical
9 PET signals (Figures S6).

10 Moreover, we conducted brain autopsy of a patient with the clinical diagnosis of
11 behavioral variant frontotemporal dementia (bvFTD), who had undergone an ^{18}F -PM-
12 PBB3 PET scan (see Supplemental Materials for clinical information). Neuropathological
13 examinations of the autopsied tissues provided a definitive diagnosis of PiD (Cairns et al.,
14 2007). Increased retentions of ^{18}F -PM-PBB3 were noticeable in frontal and temporal
15 cortices, but not in the occipital cortex (Figure 6c). Histopathological assays showed
16 numerous intraneuronal Pick bodies along with neuropil threads were doubly labeled with
17 AT8, and PM-PBB3 fluorescence in the inferior frontal gyrus, in contrast to noticeable
18 pathologies in the primary visual cortex (Figure 6c). Taken together, these data on
19 imaging-pathology relationships within a subject strongly support the capability of ^{18}F -
20 PM-PBB3 for high-contrast visualization of three- and four-repeat tau deposits in the
21 FTLD spectrum.

22

23 **Individual-based assessments of tau pathologies in living patients with diverse** 24 **FTLD phenotypes**

25 To test the feasibility of ^{18}F -PM-PBB3 for evaluations of FTLT tau pathologies on an
26 individual basis, patients with diverse clinical FTLT phenotypes (see Supplemental
27 Materials for clinical information) were scanned with this radioligand (Figure 7). The
28 absence of overt AD pathologies was confirmed by the negativity for ^{11}C -PiB-PET in all
29 these cases. As compared to a case included in the above-mentioned PSP-Richardson
30 group (top row in Figure 7), a patient with PSP parkinsonism (PSP-P), which is clinically
31 characterized by mild motor disability relative to PSP-Richardson, showed a modestly

1 increased tracer uptake confined to the subthalamic nucleus (second row in Figure 7). A
2 patient clinically diagnosed as non-AD CBS showed high radioligand binding in the
3 primary motor cortex including below white matter and subcortical regions, such as the
4 subthalamic nucleus, globus pallidus, and midbrain, with left-right asymmetry, which was
5 predominant on the side contralateral to the more affected body side (third row in Figure
6 7). These changes indicate the existence of CBD tau pathologies underlying the
7 symptomatic manifestation of CBS. Similarly, left-side dominant enhancements of
8 radioligand retention were observed in gray and white matter of the primary motor cortex
9 (i. e. precentral gyrus), and subcortical structures of a patient with progressive non-fluent
10 aphasia (PNFA) (fourth row in Figure 7). It is accordingly probable that verbal symptoms
11 in this individual represented by anarthria were chiefly attributable to CBD tau
12 pathologies involving an inferior portion of the left precentral gyrus. Furthermore, a
13 patient with bvFTD presented elevations of ^{18}F -PM-PBB3 uptake in the lateral superior
14 frontal gyrus and prefrontal cortex with little involvement of the primary motor cortex
15 and subcortical structures (bottom row in Figure 7). Taken together, the tracer
16 topographies matched with neuroanatomical variabilities of the FTL spectrum,
17 indicating that ^{18}F -PM-PBB3 could provide an accurate diagnosis based on the evaluation
18 of pathological backgrounds on an individual basis.

19 In light of the current PET observations, we constructed a schematic map illustrating
20 that the topology of ^{18}F -PM-PBB3 radiosignals is indicative of PSP, CBD, and PiD
21 pathologies as bases of five different clinical phenotypes of FTL (Figure 8;
22 clinicopathological relationships were modified from Williams and Lees, 2009 (Williams
23 and Lees, 2009)). The subcortical dominance of tau depositions characterizes
24 pathological changes in PSP, whereas a spatial expansion of areas with ^{18}F -PM-PBB3-
25 positive tau lesions to neocortical gray and white matter centralized at the primary motor
26 cortex may occur with disease progression. More widespread and intense accumulations
27 in the neocortex, often with left-right asymmetry, could suggest the presence of CBD
28 pathologies provoking clinical manifestations of CBS and PNFA. CBD tau abnormalities
29 may also give rise to bvFTD phenotypes but enhanced PET signals in the frontal and
30 temporal cortices with fewer involvements of the primary motor cortex and subcortical
31 regions imply bvFTD due to PiD pathologies. Hence, PET imaging with ^{18}F -PM-PBB3

1 potentially offers identification of the tau neuropathology linked to the clinical features
2 of FTLD in each individual case.

3

4

5 **DISCUSSION**

6 Diagnostic evaluations of neurodegenerative tauopathies have been impeded by the
7 lack of one-to-one associations between diverse neuropathological and clinical
8 phenotypes. PET imaging with our novel radioligand, ^{18}F -PM-PBB3, has been proven to
9 capture a wide range of tau fibrils with different isoform compositions, conformations,
10 and ultrastructural dimensions with contrast and dynamic range adequate for individual-
11 based assessments of AD- and FLTD-spectrum syndromes. Of note is that imaging-
12 neuropathology relationships within single subjects undergoing biopsy or autopsy
13 provided compelling evidence for the ability of the present PET technology to detect tau
14 deposits in CBD, PSP, and PiD. In addition, sensitive detection of tau inclusions in a
15 tauopathy model mouse was enabled with a cellular scale by intravital two-photon laser
16 microscopy and non-labeled PM-PBB3 and with a regional scale by PET and ^{18}F -PM-
17 PBB3. This multi-scale imaging system could prove useful for non-clinical investigations
18 of neuropathologies, which can be combined with functional analyses exemplified by
19 microscopic calcium assays and macroscopic functional MRI to clarify links between tau
20 accumulations and neuronal dysfunctions from single-cell to brain-wide levels.

21 PBB derivatives exhibit unique features represented by high reactivity with three-
22 repeat or four-repeat tau assemblies in FTLD patients and mouse models (Maruyama et
23 al., 2013; Ono et al., 2017), in contrast to weak *in-vitro* and *in-vivo* labeling of these
24 aggregates with flortaucipir and its ‘second-generation’ analogs (Aguero et al., 2019;
25 Hostetler et al., 2016; Leuzy et al., 2020; Ono et al., 2017; Schonhaut et al., 2017). One
26 of the flortaucipir derivatives, ^{18}F -PI-2620, was reported to react with four- and three-
27 repeat tau inclusions in FTLD brains (Kroth et al., 2019; Matthias Brendel, 2019), but its
28 capability to sensitively visualize FTLD-spectrum tau pathologies has been controversial
29 because of a lack of compelling evidence for the agreement of radioligand retentions with
30 PSP, CBD, and PiD tau topologies. PM-PBB3 was shown to more efficiently enter the
31 brain than the original compound, PBB3, primarily owing to its higher stability against

1 metabolic conversions. The substantial uptake of unmetabolized PM-PBB3 in the brain
2 resulted in the visualization of tau lesions with a high dynamic range, which was more
3 than 2-fold of the value yielded by PBB3 in human brains. Besides the pharmacokinetic
4 properties, low retentions of radiosignals in venous sinuses and putative penetration
5 vessels in the striatum facilitate the identification of pathological changes in the use of
6 ^{18}F -PM-PBB3 as compared with ^{11}C -PBB3 (Maruyama et al., 2013). Moreover, ^{18}F -PM-
7 PBB3 was not reactive with MAO-A and MAO-B and induced no increases in the striatal
8 radioactivity related to MAO-B, unlike ^{18}F -THK5351 and allied quinoline derivatives
9 (Harada et al., 2017; Ng et al., 2017). This characteristic is also beneficial for tau PET
10 imaging without off-target radioligand binding in MAO-B-expressing reactive astrocytes
11 (Carter et al., 2012).

12 It is noteworthy that intensification and expansion of tau depositions in association
13 with the progression of AD and PSP could be illustrated by ^{18}F -PM-PBB3 PET, indicating
14 that this radioligand could illuminate tau species critically involved in deteriorations of
15 neuronal functions. Similar to previous indications of prion-like tau dissemination in AD
16 brains capturable by PET with other probes (Betthausen et al., 2020; Cho et al., 2016; Jack
17 et al., 2018; Leuzy et al., 2020; Pascoal et al., 2018; Shimada et al., 2017), ^{18}F -PM-PBB3
18 was capable of visualizing the spatial spread of tau depositions in line with Braak's tau
19 staging, with regional radioligand retentions correlated with clinical advancements
20 assessed by CDRSoB. Significantly, enhanced radiosignals in the subthalamic nucleus
21 were concurrent with the symptomatic advancement of PSP scored by PSPRS and were
22 expanded from subcortical to neocortical areas, seemingly in accordance with emergences
23 of cognitive deficits. This observation may be attributable to the propagation of tau
24 fibrillogenesis along with corticostriatal and corticothalamic connections, although
25 prionoid properties of PSP-type tau will need to be proven by longitudinal PET tracking
26 of tau aggregates in the same individuals.

27 The current data also provide evidence for the *in-vivo* performance of ^{18}F -PM-PBB3
28 as a diagnostic adjunct to the identification and differentiation of various clinical FTLTD
29 subtypes on a neuropathological basis. Indeed, distinctions between AD/PART and
30 CBD/PSP in PNFA and CBS and among AD/PART, CBD/PSP, and PiD in bvFTD were
31 allowed for each case according to the topology of PM-PBB3-positive tau deposits. Since

1 these clear separations have not been possible with the use of previous tau PET ligands
2 (Endo et al., 2019; Schonhaut et al., 2017) and other imaging modalities such as
3 volumetric MRI, the current technology paves the way for the construction of a
4 biomonitoring system for the selection of an adequate disease-modifying therapeutic.
5 This advantage will be of particularly great importance for the development and
6 implementation of treatments against glial deteriorations in consideration of astrocytic
7 and oligodendrocytic tau accumulations that predominate PSP and CBD. It is yet to be
8 clarified whether PSP and CBD are precisely differentiated in terms of regional
9 distribution and laterality of PET-detectable tau lesions, notwithstanding the fact that
10 these two disease categories occasionally display considerable overlaps at clinical and
11 neuropathological levels (Dickson, 1999).

12 To date, the application of cryo-electron microscopy has led to the revelation that tau
13 filaments are constituted of a disease-specific self-assembling portion, providing intrinsic
14 binding pockets for PET ligands (Goedert et al., 2018; Murugan et al., 2018). This
15 diversity of the interaction between distinct fibrils and ligands may not necessarily arise
16 from differences in the tau isoform composition but could stem from additional
17 conformational variations. In fact, tau assemblies in chronic traumatic encephalopathy
18 (CTE) have been found to be composed of a conformer distinct from the AD-type tau
19 filament (Falcon et al., 2019), despite the incorporation of all six isoforms in both AD
20 and CTE tau deposits. This could result in differential affinities of tau PET probes for the
21 two tau fibril species, and our pilot PET study has demonstrated sensitive detection of
22 CTE pathologies with ^{18}F -PM-PBB3 (Takahata et al., paper in preparation), which has
23 not been achieved by ^{11}C -PBB3 (Takahata et al., 2019) and flortaucipir (Mantyh et al.,
24 2020; Stern et al., 2019).

25 Along with technical benefits, several issues should also be considered regarding the
26 utilization of ^{18}F -PM-PBB3 in clinical PET scans. The accumulation of radioactivity in
27 the choroid plexus might hinder quantitative assessments of tau depositions in
28 neighboring structures, including the hippocampus, although this did not overtly
29 influence the measurement of radioligand retentions in the parahippocampal gyrus, which
30 is the area involved in tau pathologies at the earliest Braak stage. Radiosignals in the
31 choroid plexus were documented in previous works with several other tau radioligands

1 (Ikonovic et al., 2016; Johnson et al., 2016) and are likely derived from compounds
2 bound to Biondi bodies mainly composed of non-tau but yet unidentified proteins
3 (Ikonovic et al., 2016; Lowe et al., 2016). Another caveat might be photoisomerization
4 of PM-PBB3, which is similar to the reported property of PBB3 (Hashimoto et al., 2014).
5 Our data indicated that the conversion of PBB3 and PM-PBB3 to their isomers could be
6 entirely blocked using a UV-free LED light in the radiosynthesis and administration to
7 subjects, requiring small additional equipment in nuclear medicine facilities.

8 The translational research workflow with PM-PBB3 offers a seamless evaluation of
9 candidate anti-tau therapeutics (Congdon and Sigurdsson, 2018; Shoeibi et al., 2018) in
10 non-clinical and subsequent clinical settings. Comparisons between efficacies of such
11 potential drugs in animal models and humans with the same imaging-based biomarker
12 will also help refine these models in view of their resemblance to tauopathy cases.

13 To our conclusion, the new bimodal imaging agent, PM-PBB3, enabled high-contrast
14 optical and PET detection of diverse tau conformers at cellular, regional, and global scales
15 in animal brains. This probe also captured AD- and FTL D-type tau pathologies with a
16 dynamic range sufficient for differentiation and staging of tauopathy subtypes in each
17 subject, reinforcing investigations of the neuropathological basis of clinical phenotypes
18 in living tauopathy cases.

19

20 **ACKNOWLEDGEMENTS:**

21 The authors thank all patients and their caregivers for participation in this study, Kazuko
22 Suzuki, Shizuko Kawakami and Momoyo Takanashi for their assistance as clinical
23 coordinators, Yasuharu Yamamoto, Yoshikazu Nakano, Takamasa Maeda and the
24 members of the Translational Team for their support with the PET scans, Hiromi Sano
25 and Naoto Sato for their support with the MRI scans, Jun Maeda, Bin Ji, Takeharu
26 Minamihisamatsu, Shoko Uchida and Kana Osawa for their support with mouse studies,
27 the staff of the Department of Radiopharmaceuticals Development for their radioligand
28 synthesis and metabolite analysis, and Izumi Kaneko, Chieko Kurihara and Atsuo Waki
29 for the monitoring and audit of the study. We thank John Q. Trojanowski and Virginia M-
30 Y. Lee at the Center for Neurodegenerative Disease Research and Institute on Aging,
31 Perelman School of Medicine, University of Pennsylvania, and Akiyoshi Kakita and

1 Hiroshi Shimizu at the Department of Pathology, Brain Research Institute, Niigata
2 University, for kindly sharing postmortem brain tissues, Masato Hasegawa at the
3 Department of Dementia and Higher Brain Function, Metropolitan Institute of Medical
4 Science for the biochemical analysis, and APRINOIA Therapeutics Inc. for kindly
5 sharing precursor of ^{18}F -PM-PBB3. The authors acknowledge support for the recruitment
6 of patients by Shigeki Hirano and Satoshi Kuwabara at the Department of Neurology,
7 Graduate School of Medicine, Chiba University; Taku Hatano, Yumiko Motoi, Shinji
8 Saiki and Nobutaka Hattori at the Department of Neurology, Juntendo University School
9 of Medicine; Morinobu Seki, Hajime Tabuchi and Masaru Mimura at the Department of
10 Neuropsychiatry, Keio University School of Medicine; Ikuko Aiba at the Department of
11 Neurology, National Hospital Organization Higashinagoya National Hospital; Yasushi
12 Shiio and Tomonari Seki at the Department of Neurology Tokyo Teishin Hospital.

13 This study was supported in part by AMED under Grant Number JP18dm0207018,
14 JP19dm0207072, JP18dk0207026, JP19dk0207049 to M. H., and by MEXT KAKENHI
15 Grant Number JP16H05324 to M. H., JP18K07543 to H. Shimada, JP26117011 to N. S.,
16 and by JST CREST Grant Number JPMJCR1652 to M. H.

17

18 **AUTHOR CONTRIBUTIONS:**

19 K.Tagai and M.Ono conceived the experiments and wrote the paper. Y.Takado, T.S.,
20 M.Shigeta, N.S., M.H. and H.Shimada contributed to the conception and design of the
21 study. S.K., K.Takahata, M.K., H.Shinotoh, Y.Sano. and K.M. contributed to the clinical
22 studies through the collection and processing of patient samples, provided clinical data,
23 and provided insight. H.A., H.Suzuki, M.Onaya, T.T., K.A., N.Arai, N.Araki and Y.Saito
24 contributed to the brain biopsy, autopsies and their histological examinations. C.S., Y.K.
25 and M.I. contributed to the kinetic analysis. H.T., M.T. and Y.Tomita contributed to *in*
26 *vivo* two-photon fluorescence microscopy. K.K., T.K., M Okada and M.-R.Z. contributed
27 to the radioligand synthesis and metabolite analysis. M.Shimojo helped assay validation
28 and writing the manuscript.

29

30 **DECLARATION OF INTERESTS:**

31 H.Shimada., M.-R.Z., T.S., and M.H. hold patents on compounds related to the present

1 report (JP 5422782/EP 12 884 742.3/CA2894994/HK1208672).

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

1 **FIGURE LEGENDS:**
2 **Figure 1. *In vitro* binding of PM-PBB3 to tau lesions in AD, PiD, PSP and CBD.**
3 (a) Chemical structural formulae of ^{18}F -PM-PBB3 (left) and ^{11}C -PBB3 (right). (b)
4 Triple staining of tau lesions in the hippocampal formation of an AD patient (left
5 composite), the frontal cortex of a PiD patient (left composite) and the caudate/putamen
6 of PSP and CBD patients (right composite) with 25 μM of non-radiolabeled PM-PBB3,
7 GB, and AT8. NFT, neuropil threads (NT) and dystrophic neurites encompassing a
8 neuritic plaque (NP) in AD brain sections, pick body (PB) in PiD brain section, and
9 coiled body (CB), argyrophilic threads (AT), tufted astrocyte (TA) and astrocytic plaque
10 (AP) in PSP/CBD brain sections are clearly labeled with PM-PBB3. Scale bars, 20 μm .
11 (c) Autoradiographic labeling of AD brain sections including the hippocampal
12 formation and inferior temporal cortex (left) and a PSP motor cortex section (right) with
13 5 nM of ^{18}F -PM-PBB3 in the absence (top, total binding) and presence (bottom, non-
14 specific binding: NSB) of 100 μM of non-radiolabeled PBB5, an analog of PM-PBB3.
15 (d) Photomicrographs of fluorescence staining with PM-PBB3 in areas indicated by
16 squares in c. In line with autoradiographic data, NFT in the AD subiculum (1), and
17 coiled bodies and tufted astrocytes in middle gray matter layers of the PSP motor cortex
18 (3) were intensely labeled with 25 μM of non-radiolabeled PM-PBB3, in contrast with
19 the lack of overt fluorescence signals in the white matter of the AD temporal cortex (2),
20 and superficial gray matter layers of the PSP motor cortex (4). Scale bars, 20 μm . (e)
21 Total (specific + non-specific) bindings of 1 nM of ^{18}F -PM-PBB3 in AD frontal cortex
22 (closed circles) and PSP motor cortex (open circles) samples were homologously
23 blocked by non-radiolabeled PM-PBB3 with varying concentrations, and a one-site
24 binding model was employed for describing the inhibition plots. Data are mean values \pm
25 SD in four samples and are expressed as % of the averaged total binding. (f) Binding
26 parameters for ^{18}F -PM-PBB3 determined by non-linear fitting of a one-site homologous
27 blockade model to data shown in e. (g) Inhibition of total binding of 1 nM of [^{18}F]PM-
28 PBB3 by clorgiline (MAO-A inhibitor, blue triangle), selegiline (MAO-B inhibitor, red
29 square) and BTA-1 (analog of PiB, black square) in an AD frontal cortex sample. A part
30 of ^{18}F -PM-PBB3 total binding was heterologously blocked by BTA-1 with relatively
31 large K_i (379.1 nM). Total binding of ^{18}F -PM-PBB3 was not inhibited by clorgiline and

1 selegiline at varying concentrations, while K_i for clorgiline and selegiline was not
2 determined due to failures of the model fitting. Data are mean values \pm SD in four
3 samples and are expressed as % of the averaged total binding.

4

5 **Figure 2. *In vivo* performances of PM-PBB3 as a multimodal probe for optical and**
6 **PET imaging of tau aggregates in a transgenic mouse model.**

7 **(a)** Total (specific + non-specific) bindings of 1 nM of ^{18}F -PM-PBB3 in forebrain
8 samples obtained from rTg4510 transgenic (Tg, closed circles) and non-transgenic (nTg,
9 open circles) mice were homologously blocked by non-radiolabeled PM-PBB3 with
10 varying concentrations, and a one-site binding model was employed for describing the
11 inhibition plots. Data are mean values \pm SD in four samples and are expressed as cpm.

12 **(b)** *Ex vivo* autoradiographic labeling with intravenously injected ^{18}F -PM-PBB3 in 9.7-
13 month-old Tg (top) and nTg (bottom) control mice. The brains were removed at 30 min
14 after injection and were cut into sagittal slices. Significant accumulation of ^{18}F -PM-
15 PBB3 was observed in the hippocampus (arrowhead), neocortex (arrow) and striatum
16 (circle) of a Tg mouse, but not in the cerebellum (asterisk). On the other hand, no
17 significant accumulation of ^{18}F -PM-PBB3 showed in these brain areas of a nTg mouse.

18 **(c)** Postmortem triple staining of Tg brain sections used in *ex vivo* autoradiographic
19 experiment with 25 μM of non-radiolabeled PM-PBB3, GB and AT8. Numerous
20 intracellular deposits in the hippocampal (left) and neocortical (right) areas
21 corresponding to portions indicated by arrowhead and arrow, respectively, in Panel **b**
22 were strongly labeled with PM-PBB3, GB and AT8. Scale bars, 20 μm . **(d)** *In vivo* two-
23 photon laser microscopic images showing a maximum intensity projection of
24 fluorescence signals in a 3D volume of the somatosensory cortex of 8-month-old Tg
25 (top and middle) and nTg (bottom) mice. Cerebral blood vessels were labeled in red
26 with intraperitoneally administered sulforhodamine 101, and tau aggregates in the Tg
27 mouse were illuminated in green with intravenously injected non-radiolabeled PM-
28 PBB3 (top) or PBB3 (middle), in contrast to minimal retentions of PM-PBB3 in the nTg
29 mouse brain (bottom). Images were acquired before (Pre) and 5, 30, 90 and 120 min
30 after the tracer administration. Arrowheads denote the same tau inclusion detected by
31 PM-PBB3 and PBB3. Scale bars, 20 μm . **(e)** Chronological changes of fluorescence

1 signals derived from PM-PBB3 (red circles) and PBB3 (blue circles) in identical
2 neurons bearing tau aggregate in the somatosensory cortex of Tg mouse over 120 min
3 after the tracer administration in *in vivo* two-photon microscopic imaging. Fluorescence
4 signal intensities normalized accordingly to the background signals were expressed as
5 arbitrary units (a. u.), and data are mean values \pm SD in 10 neurons. (f) Coronal brain
6 images of 9-month-old Tg (top) and nTg (bottom) mice acquired by averaging dynamic
7 PET data at 40 – 60 and 10 – 30 min after intravenous administration of ^{18}F -PM-PBB3
8 (left composite) and ^{11}C -PBB3 (right composite), respectively. Brain volume data were
9 sectioned at 3 mm (left column in each composite) and 6 mm (right column in each
10 composite) posterior to the bregma to generate images containing the
11 neocortex/hippocampus and cerebellum/brainstem, respectively. PET images are
12 superimposed on individual MRI data, and voxel values represent the SUVR generated
13 using the cerebellum as reference regions for each radiotracer. (g, h) Time-radioactivity
14 curves (g; SUV) and ratio of the radioactivity uptake to the cerebellum (h; SUVR) in
15 the hippocampus of 8-9-month-old Tg (red circles) and nTg (blue circles) mice over 90
16 and 60 min after intravenous injection of ^{18}F -PM-PBB3 (left) and ^{11}C -PBB3 (right).
17 Data are mean \pm SD in three Tg or nTg animals, and the same individuals were used for
18 a head-to-head comparison of the two radiotracers.

19

20 **Figure 3. AD and PSP tau topologies visualized with high contrast by PET with**
21 **^{18}F -PM-PBB3 as compared to ^{11}C -PBB3 in the same human subjects.**

22 (a) Orthogonal ^{18}F -PM-PBB3 and coronal ^{11}C -PBB3 and ^{11}C -PiB-PET images in the
23 same HC, and AD and PSP patients. Images of the PSP patient were derived from an
24 autopsy-confirmed PSP case. Data are displayed as parametric maps for radioligand
25 SUVR. Non-thresholded ^{18}F -PM-PBB3 images are also shown in Supplemental
26 Figure S8. (b, c) Time-course changes of the radioligand uptake (b; %SUV) and
27 SUVR to the cerebellum (c) in the cerebellum (green), temporal cortex (blue) and
28 midbrain (magenta) of representative HC, and AD and PSP patients over 150 min after
29 intravenous injection of ^{18}F -PM-PBB3. (d-f) Scatterplots demonstrating head-to-head
30 comparisons of SUVR values between ^{18}F -PM-PBB3 and ^{11}C -PBB3 in the AD (d) and
31 PSP (e) brains, and between ^{18}F -PM-PBB3 and ^{11}C -PiB in the AD brain (f). Significant

1 regression results are also shown. SUVR values were generated from four VOIs in each
2 patient.

3

4 **Figure 4. Associations between the clinical disease severity and the extent of areas**
5 **showing increased ^{18}F -PM-PBB3 binding in the AD spectrum.**

6 **(a)** Coronal ^{18}F -PM-PBB3-PET images of HCs and AD patients classified into different
7 Braak tau stages. **(b)** The topology of increased ^{18}F -PM-PBB3 binding in subjects at each
8 Braak stage compared to 22 HCs (stage zero). $p < 0.005$, uncorrected, for one HC (stage
9 I/II); $p < 0.05$, family-wise error corrected at cluster level, for four MCI/AD patients (stage
10 III/IV) and for 13 MCI/AD patients (stage V/VI). **(c)** Comparisons of ^{18}F -PM-PBB3
11 binding in Braak stage VOIs between 23 HCs (white circles) and three MCI (black
12 squares) and 14 AD (black triangles) cases. *, $p < 0.001$ by two-sample t test. **(d)**
13 Correlation of ^{18}F -PM-PBB3 binding in the Braak stage V/VI VOI with CDRSoB points
14 in MCI (black squares) and AD (black triangles) patients. $r = 0.671$ and $p = 0.003$ by
15 Pearson's correlation analysis. Associations between the clinical disease severity and the
16 extension of ^{18}F -PM-PBB3 binding among MCI/AD patients.

17

18 **Figure 5. Associations between clinical disease severity and the extension of ^{18}F -PM-**
19 **PBB3 binding in PSP-Richardson patients.**

20 **(a)** Coronal (upper) and axial (lower) ^{18}F -PM-PBB3-PET images of HC and PSP-
21 Richardson patients with different disease severities scored by PSPRS. The red
22 arrowheads point to the choroid plexus. PSP patients showed intensification of ^{18}F -PM-
23 PBB3 binding in the subthalamic nucleus and neighboring thalamic and basal ganglia
24 areas (yellow arrowhead) and midbrain (green arrowhead) and expansion to the primary
25 motor and adjacent cerebral cortices containing white matter (white arrowhead) along
26 with the clinical advancement. The asterisked image was derived from an autopsy-
27 confirmed PSP case. **(b)** Voxel-based analyses of brain atrophy (voxel-based
28 morphometry, VBM; red), ^{18}F -PM-PBB3 signal increase (green), and their spatial
29 overlaps (yellow) in PSP-Richardson patients relative to HCs ($p < 0.05$, family-wise error
30 corrected at cluster level). Statistical maps are displayed in the Montreal Neurological
31 Institute coordinate space. **(c)** Comparisons of ^{18}F -PM-PBB3 uptake in subcortical VOIs,

1 including the globus pallidus (GP), substantia nigra (SN), raphe nucleus (RN), and
2 subthalamic nucleus (STN) between 23 HCs (white circles) and 16 PSP-Richardson
3 patients (black circles). *, $p < 0.001$ by two-sample t test. **(d)** Correlation of ^{18}F -PM-PBB3
4 SUVR values in the STN with PSPRS points. $r = 0.566$ and $p = 0.018$ by Pearson's
5 correlation analysis.

6

7 **Figure 6. PET images of ^{18}F -PM-PBB3 retentions in patients with biopsy-confirmed**
8 **CBD and autopsy-confirmed PSP and PiD.**

9 **(a)** Coronal and sagittal brain images of a 68-year-old subject clinically diagnosed as
10 having CBS (upper panels). Enhanced radioligand binding was observed in the primary
11 motor and adjacent cortices and subcortical regions, including basal ganglia, subthalamic
12 nucleus, midbrain, pons and choroid plexus (red arrowheads). Neuropathological assays
13 of biopsied tissues collected from the middle frontal gyrus revealed the existence of
14 astrocytic plaques, ballooned neurons and coiled bodies stained with RD4 and/or GB in
15 the cortex and the corticomedullary junction (lower panels), in agreement with CBD tau
16 pathologies. **(b)** Axial and coronal ^{18}F -PM-PBB3 PET images of a 65-year-old patient
17 with a clinical diagnosis of PSP-Richardson (upper panels). The radioligand binding was
18 augmented in the midbrain, subthalamic nucleus, neighboring subcortical structures and
19 choroid plexus (red arrowheads). Brain autopsy conducted two years after the PET scan
20 demonstrated abundant accumulation of tufted astrocytes stained with non-radiolabeled
21 PM-PBB3, AT8, and GB in the midbrain tegmentum and subthalamic nucleus (lower
22 panels), indicating PSP as a definite diagnosis of this individual. **(c)** Coronal ^{18}F -PM-
23 PBB3 PET images of a 59-year-old patient clinically diagnosed with bvFTD (upper
24 panels). Accumulations of radiosignals were noticeable in the frontal cortex, in contrast
25 with the lack of radioligand binding in the occipital cortex. Brain autopsy was carried out
26 one year after the PET scan, showing great abundance of Pick bodies and neuropil threads
27 stained with non-radiolabeled PM-PBB3 and AT8 in the inferior frontal gyrus (lower
28 panels). This was in sharp distinction from the few tau pathologies in the primary visual
29 cortex (lower panels), collectively supporting a definite diagnosis of this case as PiD.
30 Scale bars, 10 μm (inset), and 100 μm .

31

1 **Figure 7. The topology of *in-vivo* ^{18}F -PM-PBB3 binding in patients with diverse**
2 **clinical subtypes of FTLD.**

3 Areas with intensified radiosignals, including the primary motor and cortices (white
4 arrowheads), basal ganglia (yellow arrowheads), subthalamic nucleus/midbrain (green
5 arrowheads) and choroid plexus (red arrowheads), are indicated in orthogonal ^{18}F -PM-
6 PBB3 PET images of individual patients. From top to bottom: a 65-year-old male
7 clinically diagnosed with PSP-Richardson and a PSPRS score of 42 points, and also
8 autopsy-confirmed PSP; a 62-year-old female clinically diagnosed with PSP-P and a
9 PSPRS score of 20 points; a 65-year-old female clinically diagnosed with non-AD CBS
10 and an MMSE score of 27 points; a 75-year-old male clinically diagnosed with PNFA and
11 an MMSE score of 30 points; and a 72-year-old female clinically diagnosed with bvFTD
12 and an MMSE score of 11 points.

13

14 **Figure 8. A schematic presentation of PET-detectable tau topologies in association**
15 **with clinical and neuropathological nosologies of FTLD syndromes.**

16 Three tau neuropathologies underlie five clinical phenotypes, and the neocortex-to-
17 subcortex gradient of tau depositions varies as a function of clinicopathological entity and
18 progression of the disease. Patients whose symptomatic manifestations are confined to
19 parkinsonism are likely to exhibit ^{18}F -PM-PBB3 binding localized to subcortical areas
20 (rightward), while patients with cortical symptoms such as apraxia and aphasia may
21 frequently display the radioligand binding primarily in the frontotemporal cortex
22 (leftward).

1 **STAR★METHODS:**

2 **CONTACT FOR REAGENT AND RESOURCE SHARING**

3 Further information and requests for resources and reagents should be directed to and
4 will be fulfilled by the Lead Contact, Makoto Higuchi (higuchi.makoto@qst.go.jp)

5

6 **EXPERIMENTAL MODEL AND SUBJECT DETAILS**

7 **Mice**

8 The parental P301L tau responder line, parental tTA activator line, and the resultant F1
9 rTg4510 mice and littermates were generated and maintained as previously described
10 (Ishikawa et al., 2018; Santacruz et al., 2005). All mice studied here were maintained and
11 handled in accordance with the National Research Council's Guide for the Care and Use
12 of Laboratory Animals. Protocols for the present animal experiments were approved by
13 the Animal Ethics Committees of the National Institute of Radiological Science. All
14 procedures involving live mice received prior approval from the Institutional Animal
15 Care and Use Committee of the University of Florida.

16

17 **Human subjects**

18 We included 23 HCs and 39 patients with diverse tauopathies - AD and FTLD spectrum
19 in the present study. All HCs were without a history of neurologic and psychiatric
20 disorders. Three MCI patients and 14 AD patients met Petersen's criteria (Petersen et al.,
21 1999) and NINDS-ADRDA criteria, respectively (McKhann et al., 1984). Seventeen PSP
22 patients were clinically diagnosed according to the Movement Disorder Society new
23 diagnostic criteria (Hoglinger et al., 2017) and classified into each clinical variant: 16
24 PSP-Richardson and one PSP-P. Five other FTLD spectrum; two CBS, one PNFA and
25 two bvFTD, were also diagnosed according to established criteria (Armstrong et al., 2013;
26 Gorno-Tempini et al., 2011; Rascovsky et al., 2011). In the present study, HCs and FTLD
27 spectrum patients required PiB (-) to exclude preclinical and co-pathological AD, whereas
28 MCI and AD patients needed PiB (+) by visual assessment. In addition, diagnoses of
29 some patients were also validated according to their neuropathological examinations. One
30 CBS patient was confirmed with CBD according to brain tissue biopsy before the PET
31 scan (Arakawa et al., 2020); each of the PSP-Richardson and bvFTD patients was also

1 neuropathologically diagnosed as PSP and PiD (Cairns et al., 2007) by autopsies after two
2 years and one year after each PET scan, respectively.

3 Written informed consents were obtained from all subjects and/or from spouses or other
4 close family members when subjects were cognitively impaired. This study was approved
5 by the Radiation Drug Safety Committee and National Institutes for Quantum and
6 Radiological Science and Technology Certified Review Board of Japan. The study was
7 registered with UMIN Clinical Trials Registry (UMIN-CTR; number 000030248).

8

9 **METHOD DETAILS**

10 **Compounds and Antibodies**

11 PM-PBB3 1-fluoro-3-((2-((1*E*,3*E*)-4-(6-(methylamino)pyridine-3-yl)buta-1,3-dien-1-
12 yl)benzo[*d*]thiazol-6-yl)oxy)propan-2-ol (Figure. 1a) and tosylate precursor of ¹⁸F-PM-
13 PBB3 protected with tert-Butyloxycarbonyl group and 2-tetrahydropyranyl group (Figure.
14 S1) were custom-synthesized (Nard Institute). The precursor of ¹⁸F-PM-PBB3 was also
15 provided by APRINOIA Therapeutics Inc. PBB3 (2-((1*E*,3*E*)-4-(6-
16 (methylamino)pyridine-3-yl)buta-1,3-dienyl)benzo[*d*]thiazol-6-ol) (Figure.1a) and
17 desmethyl precursor of ¹¹C-PBB3 were also custom-synthesized (Nard Institute)
18 (Maruyama et al., 2013). The reference standard for ¹¹C-PiB, 6-OH-BTA-1, is
19 commercially available (ABX), and the desmethyl precursor of ¹¹C-PiB protected with
20 methoxymethyl group, 6-MOMO-BTA-0, was custom-synthesized (KNC Laboratories).
21 PBB5 (Maruyama et al., 2013), BTA-1, clorgiline and selegiline are commercially
22 available (Sigma-Aldrich). A monoclonal antibody against tau phosphorylated at Ser 202
23 and Thr 205 (AT8, Endogen) and four-repeat tau isoform (RD4, Upstate) are
24 commercially available.

25

26 **Postmortem brain tissues**

27 Postmortem human brains were obtained from autopsies carried out at the Center for
28 Neurodegenerative Disease Research of the University of Pennsylvania Perelman School
29 of Medicine on patients with AD, PiD, PSP and CBD, and at the Department of Neurology
30 at the Chiba-East National Hospital on patients with PSP. Tissues for homogenate binding
31 assays were frozen, and tissues for histochemical, immunohistochemical and

1 autoradiographic labeling were frozen or fixed in 10% neutral buffered formalin followed
2 by embedding in paraffin blocks.

3

4 **Radiosynthesis**

5 ^{11}C -PBB3 was radiosynthesized using its desmethyl precursor, as the method
6 previously described (Maruyama et al., 2013). Radiolabeling of ^{18}F -PM-PBB3 was
7 performed as the synthetic pathway described in Figure. S1. Tosylate precursor of ^{18}F -
8 PM-PBB3 was reacted with ^{18}F -fluoride in the presence of dimethyl sulfoxide, K_2CO_3
9 and and K222 at 110°C for 15 min. After cooling the reaction vessel to 90°C , hydrochloric
10 acid was added to the mixture and maintained for 10 min to delete the protecting groups.
11 Sodium acetate was added to the reaction vessel, and the radioactive mixture was
12 transferred into a reservoir for high-performance liquid chromatography (HPLC)
13 purification (Waters Atlantis prep T3 column, 10×150 mm; $\text{CH}_3\text{CN}/50$ mM $\text{AcONH}_4 =$
14 $4/6$, 5 ml/min). The fraction corresponding to ^{18}F -PM-PBB3 was collected in a flask
15 containing 25% ascorbic acid solution and Tween 80, and was evaporated to dryness
16 under a vacuum. The residue was dissolved in 17 ml of saline (pH 7.4) to obtain ^{18}F -PM-
17 PBB3 as an injectable solution. The final formulated product was radiochemically pure
18 ($\geq 95\%$) as detected by analytic HPLC (Waters Atlantis prep T3 column, 4.6×150 mm;
19 $\text{CH}_3\text{CN}/50$ mM $\text{AcONH}_4 = 4/6$, 1 ml/min). The specific activity of ^{18}F -PM-PBB3 at the
20 end of synthesis was 58-761 GBq/ μmol , and ^{18}F -PM-PBB3 maintained its radioactive
21 purity exceeding 90% for over 3 hr after formulation. Radiolabelling of ^{11}C -PiB was
22 performed as previously described (Maeda et al., 2011).

23 PBB3 is known to undergo photo-isomerization under ordinary fluorescent light
24 (Hashimoto et al., 2014). ^{18}F -PM-PBB3 and ^{11}C -PBB3 in a colorless vial were isomerized
25 by exposure to the fluorescent light for 30 min (Figure. S7a and b, left). UV-VIS
26 absorption spectra for PM-PBB3 and PBB3 indicated that these compounds do not absorb
27 light with wavelength longer than 500 nm (Figure. S7c). Then, ^{18}F -PM-PBB3 and ^{11}C -
28 PBB3 in a colorless vial were placed under a UV-cut light (<500 nm wavelength cutoff,
29 ECOHiLUX HES-YF, 2200 lm, Iris Oyama Inc.) for 30 min, and both compounds were
30 found to be stable under this condition (Figure. S7a and b, right). Based on these results,
31 radiosyntheses of ^{18}F -PM-PBB3 and ^{11}C -PBB3 and all experiments with these

1 compounds were performed under the UV-cut light to avoid photo-isomerization of these
2 compounds.

3

4 ***In vitro* and *ex vivo* autoradiography**

5 *In vitro* autoradiography was performed using 6- μ m-thick deparaffinized sections
6 derived from AD and 20- μ m-thick fresh frozen sections post-fixed in 4%
7 paraformaldehyde solution derived from PSP brains. For labeling with ^{18}F -PM-PBB3,
8 sections were pre-incubated in 50 mM Tris-HCl buffer, pH 7.4, containing 20% ethanol
9 at room temperature for 30 min, and incubated in 50 mM Tris-HCl buffer, pH 7.4,
10 containing 20% ethanol and 5 nM of ^{18}F -PM-PBB3 (specific radioactivity: 58 GBq/ μ mol)
11 at room temperature for 60 min. The samples were then rinsed with ice-cold Tris-HCl
12 buffer containing 20% ethanol twice for 2 min, and dipped into ice-cold water for 10 sec.
13 For *ex vivo* autoradiography, Tg and nTg wild type at 9.7 months of age were anesthetized
14 with 1.5% (v/v) isoflurane and given 33.3 MBq ^{18}F -PM-PBB3 (specific radioactivity:
15 248.4 GBq/ μ mol) by syringe via tail vein. The animals were killed by decapitation at 30
16 min after tracer administration. Brain was harvested and cut into 20- μ m-thick sections on
17 a cryostat (HM560; Thermo Fisher Scientific).

18 The sections labeled with ^{18}F -PM-PBB3 were subsequently dried by treating with
19 warm air, and exposed to an imaging plate (BAS-MS2025, Fuji Film). The imaging plate
20 was scanned with a BAS-5000 system (Fuji Film) to acquire autoradiograms. Fresh
21 frozen sections generated in the process of *ex vivo* autoradiography were post-fixed in 4%
22 paraformaldehyde solution for the subsequent histological examination.

23

24 **Histological examination**

25 For fluorescence labeling, deparaffinized sections and sections used for
26 autoradiography were incubated in 50% ethanol containing 25 μ M of non-radiolabeled
27 PM-PBB3 at room temperature for 30 min. The samples were rinsed with 50% ethanol
28 for 5 min, dipped into distilled water twice for 3 min, and mounted in non-fluorescent
29 mounting media (VECTASHIELD, Vector Laboratories). Fluorescence images were
30 captured using a DM4000 microscope (Leica) equipped with a custom filter cube for
31 PBB3 (excitation band-pass at 414/46 nm and suppression low-pass with 458 nm cutoff)

1 (Ono et al., 2017). Following microscopy, sections were autoclaved for antigen retrieval,
2 and immunostained with AT8. Immunolabeling was then examined using DM4000.
3 Finally, the tested samples were used for GB staining with Nuclear Fast Red (Sigma-
4 Aldrich) counter-staining after pretreatment with 0.25% KMnO₄ followed by 2% oxalic
5 acid.

6

7 ***In vivo* two-photon fluorescence microscopy**

8 Two weeks before the measurement, surgery to create cranial windows was performed.
9 For this procedure, the animals were anesthetized with a mixture of air, oxygen, and
10 isoflurane (3-5% for induction and 2% for surgery) via a facemask, and a cranial window
11 (3-4 mm in diameter) was attached over the left somatosensory cortex, centered at 1.8
12 mm caudal and 2.5 mm lateral from the bregma, according to the ‘Seylaz-Tomita method’
13 (Tomita et al., 2005). A custom metal plate was affixed to the skull with a 7-mm-diameter
14 hole centered over the cranial window.

15 Sulforhodamine 101 (MP Biomedicals) dissolved in saline (10 mM) was injected
16 intraperitoneally (8 µl/g body weight) just before initiation of the imaging experiments.
17 The awake animals were placed on a custom-made apparatus, and real-time imaging was
18 conducted by two-photon laser-scanning microscopy (TCS-SP5 MP, Leica) with an
19 excitation wavelength of 900 nm. Two-photon imaging was performed before and 5, 30,
20 60, 90 and 120 min after intravenous injection of 0.05 mg of PM-PBB3 and PBB3
21 dissolved in dimethyl sulfoxide : saline = 1 : 1 (0.05% W/V). An emission signal was
22 separated by a beam splitter (560/10 nm) and simultaneously detected through a band-
23 pass filter for sulforhodamine 101 (610/75 nm) and PM-PBB3 and PBB3 (525/500 nm).
24 A single image plane consisted of 1024 by 1024 pixels, and in-plane pixel-size was 0.25–
25 0.45µm depending on an instrumental zoom factor. Images were acquired at a depth of
26 0.2–0.4 mm from the cortical surface. In each resulting images from Tg mouse,
27 fluorescence intensity from 10 randomly selected fluorescence-labeled pathologies were
28 measured by ImageJ, and the average was calculated after background normalization. It
29 should be noted that the background intensity of each image was acquired by averaging
30 the fluorescence intensity at 10 randomly selected areas where no fluorescence-labeled
31 pathologies were found.

1

2 ***In vivo* PET imaging in mice**

3 PET scans were performed using a microPET Focus 220 animal scanner (Siemens
4 Healthcare) providing 95 transaxial slices 2.0 mm (center-to-center) apart, a 19.0-cm
5 transaxial field of view (FOV), and a 7.6-cm axial FOV. Prior to the scans, Tg and nTg
6 mice at 8-9 months of age (n = 3 each) were anesthetized with 1.5% (v/v) isoflurane.
7 Emission scans were carried out for 90 min (^{18}F -PM-PBB3) or 60 min (^{11}C -PBB3) in 3D
8 list mode with an energy window of 350-750 keV, immediately after intravenous injection
9 of ^{18}F -PM-PBB3 (28.3 ± 10.3 MBq) or ^{11}C -PBB3 (29.7 ± 9.3 MBq). All list-mode data
10 were sorted into 3D sinograms, which were then Fourier-rebinned into 2D sinograms
11 (frames for ^{18}F -PM-PBB3: 4×1 , 8×2 , and 14×5 min, frames for ^{11}C -PBB3: 10×1 , 6
12 $\times 5$, and 2×10 min). Average images were generated with maximum *a posteriori*
13 reconstruction, and dynamic images were reconstructed with filtered backprojection
14 using a 0.5-mm Hanning filter. VOIs of hippocampus and cerebellum were placed using
15 PMOD image analysis software (PMOD Technologies Ltd) with reference to the
16 individual MR image.

17

18 ***In vitro* binding assay**

19 Frozen tissues derived from the frontal cortex of an AD patient, the motor cortex of a
20 PSP patient and the forebrain of Tg and nTg mice were homogenized in 50 mM Tris-
21 HCl buffer, pH 7.4, containing protease inhibitor cocktail (cOmpleteTM, EDTA-free,
22 Roche), and stored at -80°C pending analyses. To assay radioligand binding with
23 homologous or heterologous blockade, these homogenates (100 μg tissue) were
24 incubated with 1 nM ^{18}F -PM-PBB3 (specific radioactivity: 257.2 ± 22.2 GBq/ μmol) in
25 the presence or absence of non-radiolabeled PM-PBB3, BTA-1, clorgiline and selegiline
26 at varying concentrations ranging from 10^{-11} - 10^{-6} M in Tris-HCl buffer containing 10%
27 ethanol, pH 7.4, for 30 min at room temperature. Non-specific binding of ^{18}F -PM-PBB3
28 was determined in the presence of 5×10^{-7} M PM-PBB3. Samples were run in
29 quadruplicates and specific radioligand binding was determined as pmol/g tissue. K_i was
30 determined by using non-linear regression to fit a concentration-binding plot to one-site
31 binding models derived from the Cheng-Prusoff equation with GraphPad Prism version

1 5.0 (GraphPad Software), followed by F-test for model selection. K_d and B_{max} were
2 calculated from homologous competitive binding using this function:

3 $K_d = K_i = IC_{50} - [Radioligand]$

4 $B_{max} = \frac{Top - Bottom}{[Radioligand]/(K_d + [Radioligand])}$

5 where IC_{50} and $[Radioligand]$ are concentration of the competitor inducing 50%
6 inhibition and radiotracer concentration, respectively, and Top and Bottom are upper and
7 lower plateaus of the plot curve, respectively.

8

9 ***In vivo* MRI and PET Imaging in Human Subjects**

10 MR images were acquired with a 3-T scanner, MAGNETOM Verio (Siemens
11 Healthcare). Three-dimensional volumetric acquisition of a T1-weighted gradient echo
12 sequence produced a gapless series of thin sagittal sections (TE = 1.95 ms, TR = 2300 ms,
13 TI = 900 ms, flip angle = 9°, acquisition matrix = 256×256×250, voxel size=1×1×1mm).
14 PET assays were conducted with a Biograph mCT flow system (Siemens Healthcare),
15 which provides 109 sections with an axial field of view of 16.2 cm. The intrinsic spatial
16 resolution was 5.9 mm in-plane and 5.5 mm full-width at half-maximum axially. Images
17 were reconstructed using a filtered back projection algorithm with a Hanning filter (4.0
18 mm full-width at half-maximum).

19 ^{18}F -PMPBB3 had an average injected dose of 189.5 ± 22.5 MBq with a molar activity
20 at the time of injection of 238.5 ± 71.8 GBq/ μ mol. ^{18}F -PM-PBB3 PET scans were
21 performed with two steps of scan protocol. Of the first protocol, dynamic PET scans with
22 arterial blood sampling were performed with two imaging sessions of 60 min each with a
23 30 min break between sessions (0–60 and 90–150 min). The dynamic scan consisted of
24 12×10 s, 2×30 s, 7×1 min, 1×2 min, 1×3 min, 3×5 min, 3×10 min for the initial 60-min
25 session, and 6×10-min frames for the second 60-min session. Of the second protocol, a
26 20-min PET acquisition was performed 90 min after injections (4×5-min frames) (see
27 also Supplemental Materials).

28 ^{11}C -PBB3 and ^{11}C -PiB PET scans were performed following a previously reported
29 protocol (Kimura et al., 2015; Maruyama et al., 2013; Shimada et al., 2017). Seventy-
30 minute dynamic PET scans were performed after an intravenous injection of ^{11}C -PBB3

1 (injected dose: 423.1 ± 57.2 MBq, molar activity: 70.0 ± 18.6 GBq/ μmol). ^{11}C -PiB
2 (injected dose: 521.2 ± 87.3 MBq, molar activity: 81.8 ± 40.5 GBq/ μmol) PET scan was
3 conducted with a 20-min acquisition 50 min after injections; a ECAT EXACT HR+
4 scanner (CTI PET Systems, Inc.) was also utilized for ^{11}C -PiB alternatively.

5

6 **Image analyses in Human Subjects**

7 Data preprocessing was performed using PMOD 3.8 and Statistical Parametric
8 Mapping software (SPM12, Wellcome Department of Cognitive Neurology). Acquired
9 PET images were rigidly coregistered to individual T1-weighted MR images. SUVR
10 images were generated from averaged PET images at the following intervals: 30-50 min
11 (^{11}C -PBB3), 50-70 min (^{11}C -PiB) and 90-110 min (^{18}F -PM-PBB3) post injection,
12 respectively. Cerebellar gray matter was used as reference region. Regarding VOI
13 analyses, surface-based cortical reconstruction was conducted with FreeSurfer 6.0
14 (<http://surfer.nmr.mgh.harvard.edu/>) from the Desikan–Killiany–Tourville atlas (Klein
15 and Tourville, 2012), and then cortical and Braak-staging VOIs were generated.
16 Subcortical VOIs were transformed from a template atlas (Talairach Daemon atlas from
17 the Wake Forest University PickAtlas version 3.0.5) to each native space using the
18 deformation field obtained from the tissue-class segmentation of SPM12. Regarding
19 voxel-wise analysis, each image was spatially normalized to MNI (Montreal Neurologic
20 Institute) space using Diffeomorphic Anatomical Registration Through Exponentiated
21 Lie Algebra (DARTEL) algorithm. Subsequently, normalized images were smoothed
22 with a Gaussian kernel with an 8-mm full-width at half-maximum. Partial volume
23 correction was not performed in the present study.

24

25 **Characteristics of ^{18}F -PM-PBB3 in Human Subjects**

26 We explored uptake into the brain, and the dynamic range and distribution of specific
27 binding of ^{18}F -PM-PBB3. A head-to-head comparison of ^{18}F -PM-PBB3, ^{11}C -PBB3 and
28 ^{11}C -PiB was conducted in the same individuals. Regional time-activity curves as
29 standardized uptake value (SUV) and SUVR were generated over the time course of the
30 dynamic scan; in addition, linear regression analyses were performed among the regional
31 SUVR of each tracer derived from the same subjects. For AD, VOIs were set in each lobe

1 of the cerebral cortex to compare the dynamic range and distribution of specific binding
2 among the three tracers. For PSP, the same number of VOIs as for AD were set to compare
3 the dynamic range among PBB3 compounds in the subcortical structures where PSP is
4 considered to show moderate to high tau burden (Hauw et al., 1994) - globus pallidus,
5 substantia nigra, red nucleus, and subthalamic nucleus. Besides, the midbrain was also
6 used as a broad target-region for PSP (Figure. S4).

7

8 **Assessing Tau Deposits Associated with AD**

9 Progression of tau deposits in HCs, MCI and AD patients were evaluated according to
10 the image-based tau stage. We calculated SUVRs and Z scores of composite VOIs based
11 on Braak's pathological stages of neurofibrillary tangle: stages I / II (transentorhinal),
12 III/IV (limbic) and V/VI (neocortical) (Cho et al., 2016; Scholl et al., 2016).
13 Hippocampus was excluded from the analysis because of contamination of the signal
14 from off-target binding in the choroid plexus. The stage showing highest regional Z score
15 > 2.5 was assigned to the individual image-based tau stage: subjects showing lack of
16 involvement of stages I / II were classified as stages zero. Subsequently, we assessed
17 distribution of tau deposits and clinical association in each image-based tau stage. Voxel-
18 level comparisons were performed comparing stages I / II, III/IV and V/VI to stage zero.
19 Group comparisons between MCI/AD patients and HCs were also performed in each
20 VOI; in addition, regression analyses between SUVR of each VOI and CDRSoB were
21 also performed in MCI and AD patients.

22

23 **Assessing Tau Deposits Associated with PSP-Richardson**

24 Associations among tau deposits, clinical symptoms and brain atrophy were assessed.
25 Brain atrophy was estimated by voxel-based morphometry. Voxel-level comparisons
26 between PSP-Richardson patients and HCs were performed regarding distributions of tau
27 deposits and brain atrophy. Group comparisons using subcortical VOIs were also
28 conducted; in addition, regression analyses between SUVR of each VOI and PSPRS
29 scores were also performed in PSP-Richardson patients.

30

31 **QUANTIFICATION AND STATISTICAL ANALYSIS**

1 Statistical calculations with respect to VOI analyses were performed using GraphPad
2 Prism 7.0. Group comparisons of SUVR values derived from VOIs between HCs and
3 MCI/AD or PSP-Richardson groups were conducted by two-sample t-test. Pearson
4 correlation and linear regression analyses were conducted in a head-to-head comparison
5 among the respective tracers. Clinical associations were also explored by Pearson
6 correlation analysis. Furthermore, voxel-wise analyses were conducted by SPM12; we
7 used the two-sample t-test model of SPM12 for group comparisons. The extent threshold
8 was set to the expected voxels per cluster. For multiple voxel comparisons, family-wise
9 error corrections at cluster levels were applied ($p < 0.05$). All P values are shown in the
10 Figures or their legends.

11

12 **DATA AND SOFTWARE AVAILABILITY**

13 Requests for data that support the finding of this study should be directed to the Lead
14 Contact, Makoto Higuchi (higuchi.makoto@qst.go.jp) and will be available upon
15 reasonable request.

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

1 **SUPPLEMENTAL INFORMATION:**

2 Method details

3

4 Figure S1. Radiosynthesis of ^{18}F -PM-PBB3.

5 Figure S2. Radiometabolites of ^{18}F -PM-PBB3 in human subjects.

6 Figure S3. Brain uptake of ^{11}C -PBB3 in human subjects.

7 Figure S4. List of the VOIs applied to human subjects.

8 Figure S5. Axial ^{18}F -PM-PBB3 PET images of biopsy-confirmed CBD patient.

9 Figure S6. Distribution of tau lesions in autopsy brain sections of PSP patient.

10 Figure S7. UV-VIS absorption spectra and photo-isomerization of PM-PBB3 and PBB3.

11 Figure S8. Non-thresholded ^{18}F -PM-PBB3 PET images of a HC, and AD and PSP patients.

12 Table S1. Metabolite analysis of ^{18}F -PM-PBB3 and ^{11}C -PBB3 in mouse.

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

1 **REFERENCES:**

- 2
- 3 Aguero, C., Dhaynaut, M., Normandin, M.D., Amaral, A.C., Guehl, N.J., Neelamegam, R.,
4 Marquie, M., Johnson, K.A., El Fakhri, G., Frosch, M.P., and Gomez-Isla, T. (2019).
5 Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem
6 brain tissue. *Acta Neuropathol Commun* 7, 37.
- 7 Arakawa, A., Saito, Y., Seki, T., Mitsutake, A., Sato, T., Katsumata, J., Maekawa, R.,
8 Hideyama, T., Tamura, K., Hasegawa, M., and Shiio, Y. (2020). Corticobasal degeneration
9 with deep white matter lesion diagnosed by brain biopsy. *Neuropathology*.
- 10 Armstrong, M.J., Litvan, I., Lang, A.E., Bak, T.H., Bhatia, K.P., Borroni, B., Boxer, A.L.,
11 Dickson, D.W., Grossman, M., Hallett, M., *et al.* (2013). Criteria for the diagnosis of
12 corticobasal degeneration. *Neurology* 80, 496-503.
- 13 Betthausen, T.J., Kosciak, R.L., Jonaitis, E.M., Allison, S.L., Cody, K.A., Erickson, C.M.,
14 Rowley, H.A., Stone, C.K., Mueller, K.D., Clark, L.R., *et al.* (2020). Amyloid and tau imaging
15 biomarkers explain cognitive decline from late middle-age. *Brain* 143, 320-335.
- 16 Brendel, M., Schonecker, S., Hoglinger, G., Lindner, S., Havla, J., Blautzik, J., Sauerbeck, J.,
17 Rohrer, G., Zach, C., Vettermann, F., *et al.* (2017). [(18)F]-THK5351 PET Correlates with
18 Topology and Symptom Severity in Progressive Supranuclear Palsy. *Front Aging Neurosci* 9,
19 440.
- 20 Buee, L., Bussiere, T., Buee-Scherrer, V., Delacourte, A., and Hof, P.R. (2000). Tau protein
21 isoforms, phosphorylation and role in neurodegenerative disorders. *Brain Res Brain Res Rev*
22 33, 95-130.
- 23 Cairns, N.J., Bigio, E.H., Mackenzie, I.R., Neumann, M., Lee, V.M., Hatanpaa, K.J., White,
24 C.L., 3rd, Schneider, J.A., Grinberg, L.T., Halliday, G., *et al.* (2007). Neuropathologic
25 diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the
26 Consortium for Frontotemporal Lobar Degeneration. *Acta Neuropathol* 114, 5-22.
- 27 Carter, S.F., Scholl, M., Almkvist, O., Wall, A., Engler, H., Langstrom, B., and Nordberg, A.
28 (2012). Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-
29 L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-
30 FDG. *J Nucl Med* 53, 37-46.
- 31 Chien, D.T., Szardenings, A.K., Bahri, S., Walsh, J.C., Mu, F., Xia, C., Shankle, W.R., Lerner,

- 1 A.J., Su, M.Y., Elizarov, A., and Kolb, H.C. (2014). Early clinical PET imaging results with
2 the novel PHF-tau radioligand [F18]-T808. *J Alzheimers Dis* 38, 171-184.
- 3 Cho, H., Choi, J.Y., Hwang, M.S., Kim, Y.J., Lee, H.M., Lee, H.S., Lee, J.H., Ryu, Y.H., Lee,
4 M.S., and Lyoo, C.H. (2016). In vivo cortical spreading pattern of tau and amyloid in the
5 Alzheimer disease spectrum. *Ann Neurol* 80, 247-258.
- 6 Congdon, E.E., and Sigurdsson, E.M. (2018). Tau-targeting therapies for Alzheimer disease.
7 *Nat Rev Neurol* 14, 399-415.
- 8 Dickson, D.W. (1999). Neuropathologic differentiation of progressive supranuclear palsy and
9 corticobasal degeneration. *J Neurol* 246 Suppl 2, II6-15.
- 10 Endo, H., Shimada, H., Sahara, N., Ono, M., Koga, S., Kitamura, S., Niwa, F., Hirano, S.,
11 Kimura, Y., Ichise, M., *et al.* (2019). In vivo binding of a tau imaging probe, [(11) C]PBB3, in
12 patients with progressive supranuclear palsy. *Mov Disord*.
- 13 Falcon, B., Zhang, W., Murzin, A.G., Murshudov, G., Garringer, H.J., Vidal, R., Crowther,
14 R.A., Ghetti, B., Scheres, S.H.W., and Goedert, M. (2018). Structures of filaments from Pick's
15 disease reveal a novel tau protein fold. *Nature* 561, 137-140.
- 16 Falcon, B., Zivanov, J., Zhang, W., Murzin, A.G., Garringer, H.J., Vidal, R., Crowther, R.A.,
17 Newell, K.L., Ghetti, B., Goedert, M., and Scheres, S.H.W. (2019). Novel tau filament fold in
18 chronic traumatic encephalopathy encloses hydrophobic molecules. *Nature* 568, 420-423.
- 19 Fitzpatrick, A.W.P., Falcon, B., He, S., Murzin, A.G., Murshudov, G., Garringer, H.J.,
20 Crowther, R.A., Ghetti, B., Goedert, M., and Scheres, S.H.W. (2017). Cryo-EM structures of
21 tau filaments from Alzheimer's disease. *Nature* 547, 185-190.
- 22 Forrest, S.L., Kril, J.J., and Halliday, G.M. (2019). Cellular and regional vulnerability in
23 frontotemporal tauopathies. *Acta Neuropathol* 138, 705-727.
- 24 Goedert, M., Yamaguchi, Y., Mishra, S.K., Higuchi, M., and Sahara, N. (2018). Tau Filaments
25 and the Development of Positron Emission Tomography Tracers. *Front Neurol* 9, 70.
- 26 Golbe, L.I., and Ohman-Strickland, P.A. (2007). A clinical rating scale for progressive
27 supranuclear palsy. *Brain* 130, 1552-1565.
- 28 Gorno-Tempini, M.L., Hillis, A.E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S.F., Ogar,
29 J.M., Rohrer, J.D., Black, S., Boeve, B.F., *et al.* (2011). Classification of primary progressive
30 aphasia and its variants. *Neurology* 76, 1006-1014.
- 31 Harada, R., Ishiki, A., Kai, H., Sato, N., Furukawa, K., Furumoto, S., Tago, T., Tomita, N.,

- 1 Watanuki, S., Hiraoka, K., *et al.* (2017). Correlations of (18)F-THK5351 PET with post-
2 mortem burden of tau and astrogliosis in Alzheimer's disease. *J Nucl Med*.
- 3 Harada, R., Okamura, N., Furumoto, S., Furukawa, K., Ishiki, A., Tomita, N., Tago, T.,
4 Hiraoka, K., Watanuki, S., Shidahara, M., *et al.* (2016). 18F-THK5351: A Novel PET
5 Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease. *J Nucl Med* 57, 208-
6 214.
- 7 Hashimoto, H., Kawamura, K., Igarashi, N., Takei, M., Fujishiro, T., Aihara, Y., Shiomi, S.,
8 Muto, M., Ito, T., Furutsuka, K., *et al.* (2014). Radiosynthesis, photoisomerization,
9 biodistribution, and metabolite analysis of 11C-PBB3 as a clinically useful PET probe for
10 imaging of tau pathology. *J Nucl Med* 55, 1532-1538.
- 11 Hauw, J.J., Daniel, S.E., Dickson, D., Horoupian, D.S., Jellinger, K., Lantos, P.L., McKee, A.,
12 Tabaton, M., and Litvan, I. (1994). Preliminary NINDS neuropathologic criteria for Steele-
13 Richardson-Olszewski syndrome (progressive supranuclear palsy). *Neurology* 44, 2015-2019.
- 14 Hoglinger, G.U., Respondek, G., Stamelou, M., Kurz, C., Josephs, K.A., Lang, A.E.,
15 Mollenhauer, B., Muller, U., Nilsson, C., Whitwell, J.L., *et al.* (2017). Clinical diagnosis of
16 progressive supranuclear palsy: The movement disorder society criteria. *Mov Disord* 32, 853-
17 864.
- 18 Honer, M., Gobbi, L., Knust, H., Kuwabara, H., Muri, D., Koerner, M., Valentine, H., Dannals,
19 R.F., Wong, D.F., and Borroni, E. (2018). Preclinical Evaluation of (18)F-RO6958948, (11)C-
20 RO6931643, and (11)C-RO6924963 as Novel PET Radiotracers for Imaging Tau Aggregates
21 in Alzheimer Disease. *J Nucl Med* 59, 675-681.
- 22 Hostetler, E.D., Walji, A.M., Zeng, Z., Miller, P., Bennacef, I., Salinas, C., Connolly, B.,
23 Gantert, L., Haley, H., Holahan, M., *et al.* (2016). Preclinical Characterization of 18F-MK-
24 6240, a Promising PET Tracer for In Vivo Quantification of Human Neurofibrillary Tangles.
25 *J Nucl Med* 57, 1599-1606.
- 26 Ikonovic, M.D., Abrahamson, E.E., Price, J.C., Mathis, C.A., and Klunk, W.E. (2016). [F-
27 18]AV-1451 positron emission tomography retention in choroid plexus: More than "off-target"
28 binding. *Ann Neurol* 80, 307-308.
- 29 Iqbal, K., Liu, F., and Gong, C.X. (2016). Tau and neurodegenerative disease: the story so far.
30 *Nat Rev Neurol* 12, 15-27.
- 31 Ishikawa, A., Tokunaga, M., Maeda, J., Minamihisamatsu, T., Shimojo, M., Takuwa, H., Ono,

1 M., Ni, R., Hirano, S., Kuwabara, S., *et al.* (2018). In Vivo Visualization of Tau Accumulation,
2 Microglial Activation, and Brain Atrophy in a Mouse Model of Tauopathy rTg4510. *J*
3 *Alzheimers Dis* 61, 1037-1052.

4 Jack, C.R., Jr., Wiste, H.J., Schwarz, C.G., Lowe, V.J., Senjem, M.L., Vemuri, P., Weigand,
5 S.D., Therneau, T.M., Knopman, D.S., Gunter, J.L., *et al.* (2018). Longitudinal tau PET in
6 ageing and Alzheimer's disease. *Brain* 141, 1517-1528.

7 Johnson, K.A., Schultz, A., Betensky, R.A., Becker, J.A., Sepulcre, J., Rentz, D., Mormino, E.,
8 Chhatwal, J., Amariglio, R., Papp, K., *et al.* (2016). Tau positron emission tomographic
9 imaging in aging and early Alzheimer disease. *Ann Neurol* 79, 110-119.

10 Kikuchi, A., Okamura, N., Hasegawa, T., Harada, R., Watanuki, S., Funaki, Y., Hiraoka, K.,
11 Baba, T., Sugeno, N., Oshima, R., *et al.* (2016). In vivo visualization of tau deposits in
12 corticobasal syndrome by 18F-THK5351 PET. *Neurology* 87, 2309-2316.

13 Kimura, Y., Ichise, M., Ito, H., Shimada, H., Ikoma, Y., Seki, C., Takano, H., Kitamura, S.,
14 Shinotoh, H., Kawamura, K., *et al.* (2015). PET Quantification of Tau Pathology in Human
15 Brain with 11C-PBB3. *J Nucl Med* 56, 1359-1365.

16 Klein, A., and Tourville, J. (2012). 101 labeled brain images and a consistent human cortical
17 labeling protocol. *Front Neurosci* 6, 171.

18 Klunk, W.E., Wang, Y., Huang, G.F., Debnath, M.L., Holt, D.P., and Mathis, C.A. (2001).
19 Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and
20 readily enter the brain. *Life Sci* 69, 1471-1484.

21 Kouri, N., Whitwell, J.L., Josephs, K.A., Rademakers, R., and Dickson, D.W. (2011).
22 Corticobasal degeneration: a pathologically distinct 4R tauopathy. *Nat Rev Neurol* 7, 263-272.

23 Kroth, H., Oden, F., Molette, J., Schieferstein, H., Capotosti, F., Mueller, A., Berndt, M.,
24 Schmitt-Willich, H., Darmency, V., Gabellieri, E., *et al.* (2019). Discovery and preclinical
25 characterization of [(18)F]PI-2620, a next-generation tau PET tracer for the assessment of
26 tau pathology in Alzheimer's disease and other tauopathies. *Eur J Nucl Med Mol Imaging* 46,
27 2178-2189.

28 Lee, C.M., Jacobs, H.I.L., Marquie, M., Becker, J.A., Andrea, N.V., Jin, D.S., Schultz, A.P.,
29 Frosch, M.P., Gomez-Isla, T., Sperling, R.A., and Johnson, K.A. (2018). 18F-Flortaucipir
30 Binding in Choroid Plexus: Related to Race and Hippocampus Signal. *J Alzheimers Dis* 62,
31 1691-1702.

- 1 Lee, V.M., Goedert, M., and Trojanowski, J.Q. (2001). Neurodegenerative tauopathies. *Annu*
2 *Rev Neurosci* 24, 1121-1159.
- 3 Lemoine, L., Leuzy, A., Chiotis, K., Rodriguez-Vieitez, E., and Nordberg, A. (2018). Tau
4 positron emission tomography imaging in tauopathies: The added hurdle of off-target binding.
5 *Alzheimers Dement (Amst)* 10, 232-236.
- 6 Leuzy, A., Smith, R., Ossenkoppele, R., Santillo, A., Borroni, E., Klein, G., Ohlsson, T., Jogi,
7 J., Palmqvist, S., Mattsson-Carlgrén, N., *et al.* (2020). Diagnostic Performance of RO948 F
8 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From
9 Other Neurodegenerative Disorders. *JAMA Neurol.*
- 10 Lowe, V.J., Curran, G., Fang, P., Liesinger, A.M., Josephs, K.A., Parisi, J.E., Kantarci, K.,
11 Boeve, B.F., Pandey, M.K., Bruinsma, T., *et al.* (2016). An autoradiographic evaluation of AV-
12 1451 Tau PET in dementia. *Acta Neuropathol Commun* 4, 58.
- 13 Maeda, J., Zhang, M.R., Okauchi, T., Ji, B., Ono, M., Hattori, S., Kumata, K., Iwata, N., Saido,
14 T.C., Trojanowski, J.Q., *et al.* (2011). In vivo positron emission tomographic imaging of glial
15 responses to amyloid-beta and tau pathologies in mouse models of Alzheimer's disease and
16 related disorders. *J Neurosci* 31, 4720-4730.
- 17 Mantyh, W.G., Spina, S., Lee, A., Iaccarino, L., Soleimani-Meigooni, D., Tsoy, E., Mellinger,
18 T.J., Grant, H., Vandevrede, L., La Joie, R., *et al.* (2020). Tau Positron Emission Tomographic
19 Findings in a Former US Football Player With Pathologically Confirmed Chronic Traumatic
20 Encephalopathy. *JAMA Neurol.*
- 21 Maruyama, M., Shimada, H., Suhara, T., Shinotoh, H., Ji, B., Maeda, J., Zhang, M.R.,
22 Trojanowski, J.Q., Lee, V.M., Ono, M., *et al.* (2013). Imaging of tau pathology in a tauopathy
23 mouse model and in Alzheimer patients compared to normal controls. *Neuron* 79, 1094-1108.
- 24 Matthias Brendel, H.B., Thilo Van Eimeren, Kenneth Marek, Leonie Beyer, Mengmeng Song,
25 Carla Palleis, Jochen Hammes, Dorothee Saur, Matthias Schroeter, Jost-Julian Rumpf,
26 Michael Rullmann, Andreas Schildan, Marianne Patt, Jennifer Madonia, David Russell,
27 Andrew Stephens, Sigrun Roeber, Johannes Levin, Joseph Classen, Guenter Hoeglinger,
28 Peter Bartenstein, Alexander Drzezga, John Seibyl, and Osama Sabri (2019). 18F-PI2620
29 Tau-PET in Progressive Supranuclear Palsy - A multi-center evaluation. *J Nucl Med* 60, 54.
- 30 McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., and Stadlan, E.M. (1984).
31 Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under

1 the auspices of Department of Health and Human Services Task Force on Alzheimer's
2 Disease. *Neurology* 34, 939-944.

3 Murugan, N.A., Nordberg, A., and Agren, H. (2018). Different Positron Emission Tomography
4 Tau Tracers Bind to Multiple Binding Sites on the Tau Fibril: Insight from Computational
5 Modeling. *ACS Chem Neurosci* 9, 1757-1767.

6 Ng, K.P., Pascoal, T.A., Mathotaarachchi, S., Therriault, J., Kang, M.S., Shin, M., Guiot, M.C.,
7 Guo, Q., Harada, R., Comley, R.A., *et al.* (2017). Monoamine oxidase B inhibitor, selegiline,
8 reduces (18)F-THK5351 uptake in the human brain. *Alzheimers Res Ther* 9, 25.

9 Ni, R., Ji, B., Ono, M., Sahara, N., Zhang, M.R., Aoki, I., Nordberg, A., Suhara, T., and
10 Higuchi, M. (2018). Comparative In Vitro and In Vivo Quantifications of Pathologic Tau
11 Deposits and Their Association with Neurodegeneration in Tauopathy Mouse Models. *J Nucl*
12 *Med* 59, 960-966.

13 Okamura, N., Suemoto, T., Furumoto, S., Suzuki, M., Shimadzu, H., Akatsu, H., Yamamoto,
14 T., Fujiwara, H., Nemoto, M., Maruyama, M., *et al.* (2005). Quinoline and benzimidazole
15 derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer's disease. *J*
16 *Neurosci* 25, 10857-10862.

17 Ono, M., Sahara, N., Kumata, K., Ji, B., Ni, R., Koga, S., Dickson, D.W., Trojanowski, J.Q.,
18 Lee, V.M., Yoshida, M., *et al.* (2017). Distinct binding of PET ligands PBB3 and AV-1451 to
19 tau fibril strains in neurodegenerative tauopathies. *Brain* 140, 764-780.

20 Pascoal, T.A., Shin, M., Kang, M.S., Chamoun, M., Chartrand, D., Mathotaarachchi, S.,
21 Bennacef, I., Therriault, J., Ng, K.P., Hopewell, R., *et al.* (2018). In vivo quantification of
22 neurofibrillary tangles with [(18)F]MK-6240. *Alzheimers Res Ther* 10, 74.

23 Petersen, R.C., Smith, G.E., Waring, S.C., Ivnik, R.J., Tangalos, E.G., and Kokmen, E. (1999).
24 Mild cognitive impairment: clinical characterization and outcome. *Arch Neurol* 56, 303-308.

25 Rabinovici, G.D., and Miller, B.L. (2010). Frontotemporal lobar degeneration: epidemiology,
26 pathophysiology, diagnosis and management. *CNS Drugs* 24, 375-398.

27 Rascovsky, K., Hodges, J.R., Knopman, D., Mendez, M.F., Kramer, J.H., Neuhaus, J., van
28 Swieten, J.C., Seelaar, H., Dopper, E.G., Onyike, C.U., *et al.* (2011). Sensitivity of revised
29 diagnostic criteria for the behavioural variant of frontotemporal dementia. *Brain* 134, 2456-
30 2477.

31 Sahara, N., Perez, P.D., Lin, W.L., Dickson, D.W., Ren, Y., Zeng, H., Lewis, J., and Febo, M.

1 (2014). Age-related decline in white matter integrity in a mouse model of tauopathy: an in
2 vivo diffusion tensor magnetic resonance imaging study. *Neurobiol Aging* 35, 1364-1374.

3 Santacruz, K., Lewis, J., Spire, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A.,
4 DeTure, M., Ramsden, M., McGowan, E., *et al.* (2005). Tau suppression in a
5 neurodegenerative mouse model improves memory function. *Science* 309, 476-481.

6 Scholl, M., Lockhart, S.N., Schonhaut, D.R., O'Neil, J.P., Janabi, M., Ossenkoppele, R., Baker,
7 S.L., Vogel, J.W., Faria, J., Schwimmer, H.D., *et al.* (2016). PET Imaging of Tau Deposition
8 in the Aging Human Brain. *Neuron* 89, 971-982.

9 Schonhaut, D.R., McMillan, C.T., Spina, S., Dickerson, B.C., Siderowf, A., Devous, M.D., Sr.,
10 Tsai, R., Winer, J., Russell, D.S., Litvan, I., *et al.* (2017). (18) F-flortaucipir tau positron
11 emission tomography distinguishes established progressive supranuclear palsy from controls
12 and Parkinson disease: A multicenter study. *Ann Neurol* 82, 622-634.

13 Shimada, H., Kitamura, S., Shinotoh, H., Endo, H., Niwa, F., Hirano, S., Kimura, Y., Zhang,
14 M.R., Kuwabara, S., Suhara, T., and Higuchi, M. (2017). Association between Abeta and tau
15 accumulations and their influence on clinical features in aging and Alzheimer's disease
16 spectrum brains: A [11C]PBB3-PET study. *Alzheimers Dement (Amst)* 6, 11-20.

17 Shoeibi, A., Olfati, N., and Litvan, I. (2018). Preclinical, phase I, and phase II investigational
18 clinical trials for treatment of progressive supranuclear palsy. *Expert Opin Investig Drugs*
19 27, 349-361.

20 Soto, C., and Pritzkow, S. (2018). Protein misfolding, aggregation, and conformational strains
21 in neurodegenerative diseases. *Nat Neurosci* 21, 1332-1340.

22 Spillantini, M.G., and Goedert, M. (2013). Tau pathology and neurodegeneration. *Lancet*
23 *Neurol* 12, 609-622.







24 Stern, R.A., Adler, C.H., Chen, K., Navitsky, M., Luo, J., Dodick, D.W., Alosco, M.L., Tripodis,
25 Y., Goradia, D.D., Martin, B., *et al.* (2019). Tau Positron-Emission Tomography in Former
26 National Football League Players. *N Engl J Med* 380, 1716-1725.

27 Takahata, K., Kimura, Y., Sahara, N., Koga, S., Shimada, H., Ichise, M., Saito, F., Moriguchi,
28 S., Kitamura, S., Kubota, M., *et al.* (2019). PET-detectable tau pathology correlates with long-
29 term neuropsychiatric outcomes in patients with traumatic brain injury. *Brain*.

30 Tomita, Y., Kubis, N., Calando, Y., Tran Dinh, A., Meric, P., Seylaz, J., and Pinard, E. (2005).
31 Long-term in vivo investigation of mouse cerebral microcirculation by fluorescence confocal


1 microscopy in the area of focal ischemia. *J Cereb Blood Flow Metab* 25, 858-867.
2 Vermeiren, C., Motte, P., Viot, D., Mairet-Coello, G., Courade, J.P., Citron, M., Mercier, J.,
3 Hannestad, J., and Gillard, M. (2017). The tau positron-emission tomography tracer AV-1451
4 binds with similar affinities to tau fibrils and monoamine oxidases. *Mov Disord*.
5 Walker, L.C., and Jucker, M. (2015). Neurodegenerative diseases: expanding the prion
6 concept. *Annu Rev Neurosci* 38, 87-103.
7 Williams, D.R., Holton, J.L., Strand, C., Pittman, A., de Silva, R., Lees, A.J., and Revesz, T.
8 (2007). Pathological tau burden and distribution distinguishes progressive supranuclear
9 palsy-parkinsonism from Richardson's syndrome. *Brain* 130, 1566-1576.
10 Williams, D.R., and Lees, A.J. (2009). Progressive supranuclear palsy: clinicopathological
11 concepts and diagnostic challenges. *Lancet Neurol* 8, 270-279.
12 Zhang, W., Tarutani, A., Newell, K.L., Murzin, A.G., Matsubara, T., Falcon, B., Vidal, R.,
13 Garringer, H.J., Shi, Y., Ikeuchi, T., *et al.* (2020). Novel tau filament fold in corticobasal
14 degeneration. *Nature*.
15
16
17
18
19
20

Figure 1



f

	AD	PSP
K_D (nM)	7.63	3.44
B_{max} (pmol/g)	5743	688.2
BP	752.7	199.9






Figure 3 **^{18}F -PM-PBB3
(90 – 110 min)** **^{11}C -PBB3
(30 – 50 min)** **^{11}C -PiB
(50 – 70 min)****a**

Axial

Sagittal

Coronal

Coronal

Coronal

HC

AD

PSP

Radiotracer binding
(SUVR)

1.0

3.0

0.75

1.5

1.0

2.5

b

HC







**c****d****e****f**

Figure 4



Diagnosis	HC	HC	AD	AD
Braak	0	I / II	III/IV	V / VI
Age	55	76	75	64
CDRSoB	0	0	4.5	9








Figure 5



Compared to HCs, VBM (Red), PMPBB3 (Green), Overlap (Yellow)




Figure 6









Figure 7




Figure 8

